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Professor Douglas Melton Adriana Tajonar 
GENETIC APPROACHES TO STUDY HUMAN EMBRYONIC STEM 
CELL SELF-RENEWAL AND SURVIVAL 
Abstract 
Embryonic stem (ES) cells can be maintained indefinitely in culture while 
retaining the ability to give rise to cellular derivatives from the three germ layers. These 
unique characteristics hold great promise for regenerative medicine and underscore 
the importance of understanding the molecular mechanisms behind ES cell 
maintenance. The embryonic stem cell state is supported by a delicate equilibrium of 
mechanisms that maintain pluripotency, prevent differentiation, and promote 
proliferation and survival. We sought to find genes that could contribute to one or more 
of these processes in human ES cells by using a gain-of-function screen of over 8000 
human open reading frames (ORFs). We identify Vestigial-like 4 (Vgll4), a co-
transcriptional regulator with no previously known function in ES cells, as a positive 
regulator for survival of human ES cells. Specifically, Vgll4 protects human ES cells from 
dissociation stress, and enhances colony formation from single cells. These effects may 
be attributable in part to the ability of Vgll4 to decrease the activity of initiator and 
effector caspases. Based on global transcriptional analysis, we hypothesize that Vgll4 
enhances survival of hES cells at clonal densities by regulating changes in the 
cytoskeleton, which may in turn regulate pathways known to result in hES cell death.  
 iv 
 
This dissertation introduces a novel approach for studying hES cell survival in the 
context of cell dissociation and presents Vgll4 as a novel regulator of this process. We 
also propose that Vgll4 could have multiple functions in hES cells including possible 
roles in pluripotency, cell cycle dynamics, Hippo pathway regulation, and TGFβ 
signaling. A direct regulator of survival in human embryonic stem cells could have 
important implications for facilitating the generation of transgenic cell lines and 
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Chapter 1  
Introduction 
 
Embryonic stem (ES) cells are isolated from the inner cell mass of the developing 
blastocyst embryo. These cells have the remarkable ability to give rise to all the cell 
types in the embryo proper, a characteristic termed as pluripotency. In addition, ES 
cells can self-renew – i.e. maintain their own population by giving rise to cells with their 
same characteristics upon cell division in-vitro. Self-renewal of hES cells allows the 
expansion of a pluripotent population that can be directed to become a variety of cell 
types. Therefore, ES cells have important medical potential for cell replacement therapy 
of multiple diseases. For this reason, understanding the molecular mechanisms that 
guide cellular decisions to survive, divide, and differentiate will bring us one step closer 
to harnessing the potential of hES cells for regenerative medicine. 
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1.1 History of pluripotent cells 
1.1.1. Teratocarcinoma and embryonal carcinoma cells 
The study of pluripotent cells began in the 1950s with teratocarcinomas and 
embryonal carcinoma (EC) cells. In seminal work in the 1950s, Stevens discovered 
tumors arising spontaneously in the testes of the 129 mouse strain at very high 
incidence (1%).  These tumors contained cell types from the three developmental germ 
layers (ectoderm, mesoderm, and endoderm) [1]. In contrast to teratomas, 
teratocarcinomas are considered malignant tumors as they contain a population of 
undifferentiated embryonal carcinoma cells capable of propagating the tumor when 
transplanted into a secondary mouse recipient [2]. Studies in the late 1960s and 70s 
then found that teratocarcinomas could also be formed by transplanting pre-
gastrulation embryos into the testes or kidney of recipient adult mice [3]. In addition, it 
was determined that the cell of origin for these tumors were cells in the epiblast [4]. 
Subsequently, EC cells were adapted to culture. It is thanks to those early studies that 
the conditions for the later derivation and propagation of mouse ES (mES) cells were 
established, including the use of fibroblast feeder cells [2, 5].  
Human EC cells were derived almost concurrently to mES cells [6]. These cells also 
served as tools to model early human development and differentiation and were helpful 
for uncovering many of the molecular markers that are still used to identify pluripotent 
cells today [7]. However, the conditions in which these lines were derived and 
subsequently maintained have been found to greatly affect the propensity of different 
lines –including clonal cell lines from the same parent line – to differentiate into certain 
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lineages [5]. Interestingly, the conditions for maintaining human EC cells are very 
different from the conditions used to maintain human ES (hES) cells. These differences, 
along with the variability of their differentiation, made human EC cells less useful as a 
model for human differentiation and development. 
1.1.2. Mouse and human embryonic stem cell derivation 
In 1981, Martin Evans, Matthew Kauffman, and Gail Martin isolated embryonic 
stem cells from mouse blastocysts for the first time [8, 9]. These cells provided a more 
accurate model than EC cells to study early developmental decisions at the cellular 
level. Even though they shared many characteristics with EC cells, an interesting 
distinction was that they could contribute to the germline when transplanted into 
recipient blastocysts [10]. ECs only contributed to somatic tissues at a relatively low 
rate. Germline transmission opened the door to the field of genetic modification and the 
generation of transgenic mice. 
Human ES cells were derived in 1998 by James Thomson [11]. The lack of optimized culture 
conditions was the main reason why hES cells were not established sooner [5]. It is now clear 
that the signals that maintain hES cell self-renewal are very different from those used to 
maintain mouse ES cells, preventing the straightforward translation of knowledge gained 
with mES cells to hES cells. Nonetheless, under the appropriate conditions, embryonic stem 
cells from both species can be maintained indefinitely in culture while retaining the ability to 
give rise to cellular derivatives from the three embryonic germ layers. These two 
characteristics –self-renewal and pluripotency– have important implications for regenerative 
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medicine and exciting research is underway to guide the differentiation of these cells for cell 




1.2  Mouse embryonic stem cell self-renewal 
Two signals have been shown to sustain self-renewal in cultured mES cells: 
Leukemia Inhibitory Factor (LIF) and Bone Morphogenetic Protein (BMP). LIF and BMP 
maintain mES cell pluripotency by complementary mechanisms that activate self-
renewal and inhibit differentiation, respectively [12]. LIF signals via the gp130 cytokine 
receptor and the LIF receptor to activate JAK kinases, which, in turn, phosphorylate 
STAT3. Phosphorylated STAT3 forms a homodimer that translocates to the nucleus and 
activates transcription of target genes that promote self-renewal, including Klf4, Sall4, 
and Jmjd [13-15]. This signaling is complemented by BMP, a growth factor found in 
serum, which activates the inhibitor of differentiation (Id) genes, which in turn inhibit 
neural differentiation in mES cells [12]. Id proteins are helix-loop-helix proteins that act 
as dominant negative inhibitors of several families of transcriptional regulators, many 
of these with roles in lineage specification [16, 17]. Basic helix-loop-helix (bHLH) 
transcription factors are sequestered by Ids. Since Id proteins lack a basic DNA binding 
domain, they prevent the dimerization of bHLH factors with other tissue-specific 
partners thus hindering their binding to DNA [18]. Normally, inactivated mouse 
embryonic fibroblasts (MEFs) serve as a source of LIF and BMP is provided by the 
addition of serum to the medium. Therefore, when used together, BMP and LIF allow 
the maintenance of pure mES cell populations in feeder-free and serum-free conditions 
[12] (Figure 1-1). These conditions are advantageous because they are better defined, 
thus allowing more control of the signals provided to cells, both for maintenance and 
for directed differentiation efforts.  
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Autocrine Fibroblast Growth Factor (FGF)-4 signaling in mES cells leads to 
activation of Extracellular-signal Regulated Kinase (ERK) signaling. It is thought that 
this signal primes ES cells for differentiation into multiple lineages [19, 20]. To find a 
stable ground or naïve state for self-renewal, Austin Smith’s group used an ERK 
inhibitor to prevent this priming into lineage commitment. Additionally, Glycogen 
Synthase Kinase 3 β (GSK3-β) was inhibited to promote mES cell propagation. Together, 
inhibitors for these two pathways are known as 2i. The culture of mES cells in 2i with or 
without LIF allows serum independence and is permissive for the culture of refractive 
ES lines [19-22] and ES lines from previously non-permissive species [23]. Smith 
proposes that when mES cells are maintained with LIF and BMP, FGF4-ERK signaling is 
active, and therefore these cells are already in a primed state for differentiation. By 
inhibiting FGF4-ERK, priming is inhibited, and therefore mES cells are kept in a naïve or 
ground state of self-renewal [19, 20]. It is thought that changing culture conditions or 
overexpressing genes with known roles in pluripotency and reprogramming, such as 
Klf4 [24], can allow the conversion from naïve to primed state and vice versa, but the 
changes that occur at the molecular level and the role of the pluripotency master 




1.3  Human embryonic stem cell self-renewal and survival 
1.3.1. Self-renewal mechanisms in hES cells 
Signaling pathways involved in hES cell self-renewal –or at least their upstream 
effectors– have been shown to be divergent from the mouse. For instance, LIF signaling 
does not sustain self-renewal in hES cells. Studies have shown that even though hES 
cells are molecularly capable of responding to LIF signaling by upregulating STAT3 
phosphorylation, this does not contribute to maintenance of self-renewal [26, 27]. This 
result is not due to phosphorylation levels below an activation threshold, as the 
expression of a constitutively active form of STAT3 was not sufficient to maintain the 
undifferentiated hES cell state [26]. BMP also failed to contribute to hES cell self-
renewal, and instead caused differentiation of hES into trophectoderm. In addition to 
morphological changes, this differentiation was accompanied by upregulation of genes 
involved in trophoblast and placental development [28]. Recently, it was also shown 
that short-term BMP signaling in hES cells could lead to mesoderm differentiation [29]. 
Conversely, culturing hES cells in media containing the BMP inhibitor noggin has been 
shown to result in decreased differentiation [30].  
Activin A and Fibroblast Growth Factor (FGF) signaling pathways are now 
understood to be important for hES cell maintenance. However, it is possible that other 
pathways contributing to self-renewal remain to be discovered. Activin A has been 
shown to act synergistically with FGF2 to promote self-renewal [31-34]. Activin 
A/Nodal/TGFβ binding to the Type I and Type II receptors promotes a cross-
phosphorylation event that results in the phosphorylation and activation of Smad 2/3. 
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Activated Smad 2/3 binds to the Smad4 co-Smad and translocates to the nucleus where 
it interacts with other transcription factors to regulate gene expression [35]. A study by 
Xu and colleagues found that Smad2/3 binds to the Nanog promoter and promotes 
transcription of Nanog in hES cells [36]. Xu also showed that FGF contributed to 
proliferation and supported Nanog expression, but how it interacts with the 
pluripotency network remains to be determined. Interestingly, this study also 
uncovered the mechanism for differentiation induction by BMP in hES cells. 
Smad1/5/8, which are activated in response to BMP can also bind and inhibit the 
Nanog promoter. Overall, not only do Activin A and FGF induce each other’s 
transcription, but they also seem to act together to counteract the activity of BMP 
(Figure 1-1). 
Despite differences in the upstream signaling mechanisms that promote 
pluripotency, mouse and human ES cells depend on three master regulators of 
pluripotency: Oct4, Sox2, and Nanog. These transcription factors bind to the promoter 
region of multiple genes in ES cells [37, 38]. To maintain the ES cell state, they promote 
the expression of genes important for pluripotency and self-renewal by recruiting the 
transcriptional machinery. In addition, they inhibit genes that lead to the establishment 
of differentiation programs by recruiting chromatin-modifying proteins that promote 






Figure 1-1. Self-renewal mechanisms differ between mouse and human ES cells. Mouse ES 
cells can be maintained by LIF (acting through STAT3) and BMP (inducing Id genes) in the primed 
state. In the naïve state (indicated in blue), inhibition of ERK and GSK-3β allow the maintenance of 
mES cells in the ground state. Human ES cells are maintained by Activin/TGFβ (which act through 
Smad2/3 and promote Nanog expression) and FGF. FGF and Activin promote each other’s expression. 
Additionally, FGF might participate in the inhibition of BMP through an unknown mechanism. BMP 
promotes differentiation in hES cells by inhibiting Nanog expression. Oct4, Sox2, and Nanog 




1.3.2. Survival mechanisms in hES cells 
Besides the upstream signaling that leads to their self-renewal, another distinctive 
characteristic between human and mouse ES cells is the sensitivity of hES cells to 
dissociation leading to high levels of cell death. It is not understood why mouse ES cells 
do not share this sensitivity to dissociation stress, but some have suggested a 
differential response by cells in different developmental states – mES cells being more 
ICM-like or “naïve” and hES cells being more epiblast-like or “primed” [41]. 
Dissociation-induced cell death has been a roadblock to the application of hES cells to 
methods where clonal cells are needed, including gene manipulation and the study of 
clonal populations. In 2007 a chemical inhibitor of Rock was shown to increase survival 
of dissociated hES cells by close to 30-fold [42]. Rock inhibitor (Y-27632) is now 
commonly used in the maintenance and derivation of hES and iPS cells. 
Recently, several studies have allowed us to understand the relation between cell 
dissociation, cell death, and Rock inhibitor. In an epithelial colony, where cell-to-cell 
contacts are intact E-cadherin mediates inhibition of Active BCR-Related gene (Abr), 
and activated Ras-related C3 botulinum toxin substrate 1 (Rac) inhibits Ras homolog 
gene family members (Rho). Disruption of cell-to-cell contacts lead to the activation of 
Abr. Abr is both a Rho-GEF, catalyzing the activation of Rho by binding of GTP and a 
Rac-GAP, inactivating Rac by GTP hydrolysis. Therefore, Rac is inactivated and Rho is 
activated. Activated Rho leads to the activation of Rho-associated kinase (Rock), which 
phosphorylates myosin. This leads to myosin hyperactivation, manifested as blebbing of 
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the cell membrane and preceding caspase activation and cell death in hES cells [41, 43, 




Figure 1-2. Cell dissociation promotes apoptosis in hES cells. E-cadherin-mediated cell-to-
cell junctions inhibit Abr. When cell-to-cell junctions are disrupted, Abr activates Rho and inhibits 
Rac. Rho activates Rock, which phosphorylates myosin, leading to myosin hyperactivation and 





1.4 Induced pluripotent stem cells 
Work in cloning and somatic cell nuclear transfer showed that the nucleus of an 
adult cell retained the potential to give rise to an entire organism when placed in an 
enucleated oocyte [45]. This experiment revealed that the genome of a cell was not 
irreversibly changed during development. For several decades, research focused on 
finding the combination of factors that made this possible in the oocyte.  
A breakthrough by Takahashi and Yamanaka in 2006 [46] found that co-
expression of Oct4, Sox2, Klf4, and c-Myc –four transcription factors known to be 
important in pluripotent cells– could reprogram an adult fibroblast into an embryonic 
stem cell state. These induced pluripotent stem (iPS) cells were assessed for their 
pluripotent ability by the pluripotent marker expression, teratoma formation, and 
contribution to developing tissues in chimeric mice. This combination of factors was 
found to also reprogram human fibroblasts [47-49]. iPS cells allow the derivation of 
patient-specific pluripotent cells, therefore circumventing the biological and ethical 
roadblocks of producing them by other means. Before the discovery of iPS cells, the 
alternative for obtaining patient-specific pluripotent cells was somatic cell nuclear 
transfer (SCNT). SCNT is the technology used to clone Dolly the sheep and involves 
injecting a somatic cell nucleus is into an enucleated oocyte to obtain blastocysts [45]. 
These blastocysts can then be used to derive ES lines, or as in the case of Dolly, be 
implanted into the uterus of a recipient mother for organism development. Besides 
being very inefficient [50, 51], SCNT has obvious shortcomings in humans, including the 
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accessibility of oocytes for nuclear injection [52] and the fact that many consider it “too 
close a step” in cloning humans.  
The factors used to reprogram fibroblasts, have since been shown to reprogram a 
variety of adult cell types to pluripotency [53-55]. Additionally, much progress and 
numerous technological advances have happened since to improve reprogramming 
efficiency from an initial 0.001% to up to 4.4% [56]. Currently, intense research is in 
progress to determine whether ES cells and iPS cells are functionally equivalent. Some 
have suggested that the transcriptional and epigenetic differences between these 
populations have to do with their different derivation histories [56]. Nevertheless, they 
are both valuable pluripotent populations with the potential to make the goals of 




1.5 Genetic screening approaches to understanding self-
renewal 
Screening provides a broad, high-throughput approach to discovering genes 
involved in a particular biological process.  A few studies have undertaken a genetic 
screening approach to discover genes involved in the maintenance of self-renewal in 
hES cells. These studies, however, have focused on a loss-of-function approach, where 
the use of siRNA has allowed for the discovery of genes necessary for the hES cell state. 
Of note is a study by Chia and colleagues [57]. This study used a hES cell line with a GFP 
reporter under the control of the Oct4 promoter. This study surveyed over 21,000 
shRNAs in a primary assay. 200 candidates were selected for further verification based 
on their ability to downregulate GFP levels and their gene ontology categories. PR-
domain-containing 14 (PRDM14) was identified as a co-transcriptional regulator with a 
role in regulating the transcription of Oct4 and the ability to increase the efficiency of 
reprogramming. This study serves as a proof-of-principle for the use of loss-of-function 
genetic screens for gene discovery in hES cells. 
Despite the advantages provided by screening approaches, no gain-of-function 
studies have been reported for hES cells. Interestingly, Nanog was discovered using a 
small-scale gain-of-function screen in mouse ES cells [58]. In this approach a cDNA 
library was produced from mouse ES cells to look for genes that could overcome 
ablation of the LIF-receptor. The reader might wonder why genetic gain-of-function 
screens have not been a popular approach for hES cells. Perhaps creating an assay for 
sufficiency in hES cells has been a roadblock for many. This could be explained by the 
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observation that many genes, including Oct4 and Sox2, need to be expressed at carefully 
defined levels to maintain pluripotency and deviation from these levels results in 
differentiation [59-62]. An alternative explanation is the availability of sophisticated 
reporters in mES cells, making them a more attractive cell type to use for screening 
purposes. Researchers might prefer to verify genes discovered in mES cells instead of 
generating a screening strategy for hES cells. As this chapter outlined previously, there 
are, however, important differences between mouse and human. It is clear that there is 
much to learn about self-renewal and pluripotency in hES cells. Screening strategies are 
an efficient way to approach the puzzle, but require careful optimization of conditions 




1.6 Some current challenges and questions in the field 
Human ES and iPS cells represent a unique opportunity to attain the goal of 
regenerative medicine. If we consider the ES cell state as an equilibrium of mechanisms 
promoting self-renewal, inhibiting differentiation, and promoting proliferation and 
survival, we have only started to understand the mechanistic details of these processes 
and how they relate to each other. A deeper understanding of these mechanisms will 
allow us to better define the pluripotent state and perhaps establish whether there are 
commonalities in the maintenance and expansion of progenitor cell pools in vitro.  
Despite rapid progress in this field, central questions remain in our basic 
understanding of hES cell biology. For instance, what other pathways, besides 
Activin/TGFβ, are necessary for self-renewal?  How are these pathways maintaining the 
pluripotency network in hES cells and which combination of factors is sufficient for hES 
cell maintenance? Understanding the pathways required to maintain hES cell 
pluripotency will allow culturing of hES cells in defined conditions. Defined conditions 
have many advantages, including the ability to more efficiently direct self-renewal and 
differentiation, and the independence from animal-derived components. The field has 
progressively shifted towards culture of hES cells in the absence of MEFs and serum. 
However, it is worth noting that the concentration of FGF currently used in conditioned 
media is extremely high (10 fold higher than the concentration used for hES cell 
maintenance on MEFs) [30, 63], perhaps because the molecular foundation of hES cell 
self-renewal is not entirely understood. The consequences of such high concentrations 
are unknown, for instance in terms of possible cross-reactivity with other pathways or 
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in the generation of epigenetic changes that affect the differentiation potential of 
pluripotent cells. Additionally, the connections of FGF with the pluripotency 
transcription factors are not understood.  
The molecular underpinnings of many differences between mouse and human ES 
cells are not well understood. Given that mouse ES cells, and cells in the naïve state are 
not sensitive to dissociation, we consider that gaining a better understanding of the 
mechanisms that change between the naïve and primed state would allow us to 





1.7 Overview of the dissertation 
In this dissertation, we aim to gain a better understanding into the mechanisms 
behind hES cell maintenance. Chapter 2 describes a gain-of-function screen using a 
human open-reading-frame (ORFeome) library to find genes that can overcome 
inhibition of TGFβ signaling. It also describes a verification assay for candidates 
obtained from that primary screen and the identification of Vestigial-like 4 (Vgll4) a co-
transcriptional regulator that had not been described previously in hES cells. 
Chapter 3 focuses on characterizing the role of Vgll4 in promoting survival of hES 
cells. We find that Vgll4 protects hES cells from dissociation stress and allows a higher 
survival rate. This is possibly due to the inhibition of caspase activity and perhaps 
interaction with the Rock pathway. 
Chapter 4 covers other mechanisms that were explored in the effort to 
characterize the function of Vgll4. We present data that suggests a complex mechanism 
of action for this gene and the possible involvement of other pathways and processes in 
its observed phenotype. Finally, Chapter 5 covers some overall conclusions and 
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Chapter 2  
Genetic gain-of-function screen for self-
renewal genes 
2.1 Introduction 
Pluripotency is the ability of cells such as those in the inner cell mass of the 
developing blastocyst to contribute to cell derivatives of all germ layers during 
differentiation. Cells that maintain this unique biological characteristic have been 
adapted to culture in the form of ES cells and iPS cells, representing fascinating 
therapeutic potential for multiple diseases. Despite progress in recent years, the 
molecular mechanisms that maintain the pluripotent state in human embryonic stem 
(hES) cells, remains poorly understood. This poses a challenge for the maintenance and 
directed differentiation of these cells into clinically relevant populations. We decided to 
take a broad approach to address the problem of finding new genes involved in 
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maintaining the pluripotent state. For this purpose we conducted a biological gain-of-
function screen to identify genes that contribute to this process. This chapter will 
provide a brief description of the library used for this approach, followed by the 
identification of screening conditions and controls. Finally, this chapter will describe 
the primary and secondary assays used to discover candidate genes. 
The goal of the gain-of-function screen is to find genes that maintain hES cell 
pluripotency under differentiation conditions. We reason that if a gene is able to 
prevent a cell from differentiating while allowing it to retain an ES cell phenotype, this 
gene could be part of the pluripotency maintenance network (Figure 2-1). A similar 
approach was used previously to discover Nanog in mES cells [1]. In this study, LIF 
signaling –one of the signals that maintains mES cell self renewal (please refer to 
Chapter 1 for more details)– was ablated by mutation of the LIF-receptor. A cDNA 
library for genes expressed in mES cells was then used to find genes that could maintain 
mES cell pluripotency in the absence of irradiated mouse embryonic fibroblasts (MEFs) 
and LIF. 
Dr. René Maehr in our lab led an effort to generate a human open reading frame 
(ORF)-eome library in lentiviral vectors optimized for expression in mammalian cells. 
To this end, a human ORFeome library from the Center for Cancer Systems Biology 
Human ORFeome Collection (horfdb.dfci.harvard.edu) was subcloned into a pHAGE 
vector [2, 3] adapted for Gateway cloning by the addition of attR sites. 
This first version of the ORFeome contains 8,076 ORFs, representing 7,263 genes. 
All ORFs are tagged with Hemagglutinin (HA) on the C-terminus. The pHAGE vector 
contains an EF1α promoter that drives the ORF in question. The EF1α promoter has 
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been shown to drive strong expression in hES cells and multiple differentiated cells [4]. 
In addition, a PGK promoter drives expression of the puromycin-resistance gene, 











Figure 2-1. A gain-of-function strategy to discover novel genes involved in the 
maintenance of hES cells. HUES6 cells transduced with lentiviruses carrying a hORFeome library 
containing approximately 8000 genes (Table S1) were subjected to three weeks of treatment with 
10µM TGFβ inhibitor (TGFβi). Colonies with characteristic ES cell morphology after such treatment 
were picked and their DNA was sequenced to identify 75 preliminary candidates 
 
 
Figure 2-2. A Gateway-adapted pHAGE vector to efficiently promote gene expression in 
hES cells. The hORFeome library is contained in a lentiviral vector. The gene of interest is driven by 
an EF1α promoter and the ORF is fused to a hemagglutinin (HA) tag. In addition, this lentiviral vector 
carries a puromycin resistance gene driven by a PGK promoter. Primer binding sites are indicated by 




2.2 Primary screen 
2.2.1. Experimental Design 
A. Establishment of permissive conditions 
The choice of appropriate screening conditions allows for the discovery of 
candidates involved in a particular process of interest. We chose to utilize chemical 
inhibitors for signaling pathways important in the maintenance of hES cell 
pluripotency. We reasoned that such conditions would allow us to uncover genes with a 
role in the maintenance of the pluripotent state in hES cells. 
The TGFβ signaling pathway has been shown to be necessary for the maintenance 
of pluripotency in hES cells[5-8]. Subsequent studies have shown that Activin/Nodal 
signaling enhances Nanog expression by binding of Smad 2/3 to its promoter[9]. We 
therefore predicted that inhibition of this pathway would drive hES cells out of the 
pluripotent state and towards differentiation. 
SB-431542 is a specific inhibitor of the TGFβ Type I receptors ALK4, 5, and 7[10].  
Based on previously published studies [6, 7], we used a concentration of 10 μM to 
disrupt TGFβ/Activin/Nodal signaling in hES cells. Treatment of cells with 10 μM SB-
431542 for three passages, or approximately three weeks, caused a loss of hESC 
morphology and pluripotency marker expression as assessed by microscopy and FACS 













Figure 2-3. Inhibition of TGFβ signaling results in loss of hES cell colony morphology and 
pluripotency marker expression. Cells transduced with a Nanog ORF were used as a positive control, 
cells transduced with a GFP ORF and wildtype cells were used as negative controls. a) Negative controls 
lost the characteristic hESC morphology after three weeks or 3 passages of SB-431542 (TGFβi) treatment 
(Bars = 500 µm). b) Cells transduced with GFP and treated with TGFβi for three weeks downregulate 
Tra1-60 and SSEA-3 (not shown). However, cells transduced with Nanog under this treatment retain 









Having established screening controls, we next established positive and negative 
controls for the screen. Since our screening method is a genetic gain-of-function 
approach, it was necessary to have a positive control to correctly establish our 
screening conditions and to efficiently evaluate candidates. Nanog is unique among the 
core transcription factors in hES cells in that its overexpression prevents lineage 
specification and maintains cells in a pluripotent state even in the presence of 
differentiation conditions [1, 11]. Oct4 and Sox2, the other members of the core 
pluripotency machinery maintain pluripotency at a specific concentration; an increase 
or decrease in their levels leads to differentiation [12-14]. We therefore chose Nanog 
overexpression as a positive control for pluripotency maintenance.  
GFP was chosen as a negative control. In addition to its lack of effect in 
pluripotency, it also served as a useful transfection and transduction control in our 
experiments. In follow up experiments, Tubulin was used as a negative control instead 
of GFP. This substitution was made since the absence of fluorescence facilitated assays 
where the GFP channel was needed, for example in FACS and immunocytochemistry. 
B. Library transduction 
For our screen, we transduced HUES6 hES cells with a pool of genes encompassing 
version 1.1 of the ORFeome [15].  Lentivirus carrying the ORFeome library was 
concentrated and titrated by Dr. Maehr. We transduced approximately cells by 
incubating cells and virus in a low-attachment dish for 2 hours and subsequently 
plating onto MEFs as a feeder layer. This methodology ensured a low transduction rate 
of MEFs to maximize the proportion of transduced hES cells. 2x106 hES cells were 
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transduced with 7x106 viral particles resulting in an MOI of 3 or 4. Based on these 
numbers, we estimate that our library was covered close to 1000 times, ensuring 
adequate coverage.  
C. Candidate identification 
Following transduction, cells were incubated in hES medium for 48 hours before 
selecting with 2μg/ml of puromycin. This incubation period ensured enough time for 
cell attachment, viral integration, and viral gene expression to begin. The GFP control 
allowed us to assess EF1α promoter in transduced cells. Additionally, by following the 
proportion of GFP-positive cells throughout selection, we were also able to assess PGK 
promoter activity (Figure 2-4). Following puromycin selection cells were treated with 
SB-431542 for three weeks. After this treatment, the colonies that retained hES cell 
morphology were isolated manually and lysed to obtain genomic DNA. Primers 
surrounding the ORF region were used for PCR. Gel-purified PCR products were then 






Figure 2-4. EF1α and PGK promoters drive efficient expression in hESCs. HUES6 cells were 
transduced with EF1α-GFP. Before puromycin selection cells that were not transduced are visible. 
After selecting with 2µg/ml of puromycin for 2 days, a homogenous population of GFP-expressing 




We identified 75 open reading frames (Table 2-1) that were able to maintain hES 
cell colony morphology under the differentiation conditions that we used for our 
screen. None of these genes had been previously implicated in pluripotency and they 
belong to diverse gene ontology groups. 
Interestingly, Vestigial-like 4 (Vgll4) was identified 3 independent times, an event 




















































































































































2.3 Secondary screen 
2.3.1. Introduction 
Our primary screen using a human ORFeome library allowed us to identify 75 
preliminary candidates. Individual verification of these candidates was necessary for 
several reasons: a) PCR analysis on isolated colonies revealed that the majority of the 
isolated colonies had more than one insertion. This observation can be explained by the 
fact that the primary screen was performed in a pooled fashion at an MOI of 
approximately 3.5. Additionally, ORFeome-transduced cells were passaged twice, 
raising the possibility of having colonies that are a mixture of different populations of 
cells with different insertions. b) In order to find the most robust subset of candidates 
to concentrate on for further studies and validation, we were interested in those that 
had a dominant effect independent of other factors. 
2.3.2. Experimental Design 
A. Establishment of permissive conditions 
We aimed to find conditions of increased stringency that would allow us to verify 
our preliminary candidates in a fast and efficient manner. To this end, we sought to 
identify small molecule inhibitors for pathways known to be important for hES cell 
pluripotency that, when used in combination, with SB-431532 led to a more rapid loss 
of hES cell morphology. 
TGFβ and FGF signaling have been shown to be necessary for hES cell pluripotency 
[5, 6, 16-18]. Additionally, several studies have uncovered evidence for a synergistic 
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activity of these pathways for maintaining the pluripotent state [7-9]. Therefore, we 
tested SU-5402, an inhibitor for the kinase activity of FGFR1 [19], could rapidly induce 
differentiation, either alone or in combination with SB-431542 for 5 and 7 days. 
Retinoic acid was also tested given its differentiation-inducing abilities [20, 21]. 
We found that SB-431542 and SU-5402 alone caused little differentiation after 5 
or 7 days as assessed by colony morphology, Oct4, and Tra 1-60 expression. Retinoic 
acid also had only a very mild effect at these timepoints. However, the combination of 
SB-431542 and SU-5402 caused rapid and robust differentiation, assessed by loss of 
colony morphology and widespread downregulation of Oct4. This differentiation was 







Figure 2-5. Optimization of conditions for secondary verification assay. A TGFβ inhibitor 
(SB-431542), an FGF inhibitor (SU-5402), and Retinoic Acid were tested for their ability to cause 
differentiation in 5 or 7 days. Differentiation was assessed by evaluating colony morphology, Oct4, 
and Tra 1-60 expression. At both timepoints, FGFi and Retinoic Acid had a mild effect. Treatment 
with TGFβi caused some differentiation, but a considerable number of undifferentiated cells were 
still present at both timepoints. The combination of TGFβi and FGFi caused robust loss of 




We also verified the double inhibitor treatment [10 μM TGFβi (SB-431542) and 20 
μM FGFi (SU-5402) –referred to throughout this thesis as TGFβi+FGFi for TGFβ 
inhibitor and FGF inhibitor] using our Nanog and GFP controls. In the presence of 
Nanog, cells maintained Oct4 expression and colonies retained normal morphology. As 
expected, the GFP control exhibited differentiation much like its wildtype counterpart, 








Figure 2-6. Verification of secondary screening conditions using overexpression controls. 
Combined inhibition of TGFβ and FGF causes Oct4 downregulation and loss of colony morphology (as 
shown by DAPI panel) in cells overexpressing GFP but not in cells overexpressing Nanog. GFP control 




B. Candidate verification 
Optimization of the conditions for secondary verification of our preliminary 
candidates allowed for a rapid and stringent verification of those that could overcome 
inhibition of two pathways necessary for pluripotency maintenance. To verify the 
candidates, lentiviruses were produced for each individual candidate and used to 
transduce cells at an MOI of 1-2. We then selected transduced cells using 2 μg/ml of 
puromycin. Following selection, cells were treated with TGFβi+FGFi for 5 days with 
media changes every second day. After this treatment, colony morphology, Oct4, and 
Tra 1-60 expression were assessed (Figure 2-7). 
We verified 56 out of the 75 preliminary candidates using 5 rounds of verification 
in duplicates (Figure 2-8).  
 
Figure 2-7. Identification of four positive hits using a secondary verification assay. 
Preliminary candidates were verified using a more stringent test for maintenance of the hES cell state. 
The verification assay consisted of 5 days of treatment with 10µM TGFβi in addition to 20µM FGF 
inhibitor (FGFi). DMSO was used as a vehicle control. After this treatment, qualitative analysis of 
colony morphology and expression of ES cell markers Oct4 and Tra 1-60 was assessed by 
immunostaining. Hits indicated with an asterisk here, and in Table 1-1, were those that were 




We identified four positive hits from our secondary verification assay.   
A. Vestigial-like 4 (Vgll4) 
Vgll4 is a co-transcriptional regulator of Transcription Enhancer Factors (TEF) 
transcription factors. The only described function for Vgll4 in mammals to date is a role 
in regulating transcription downstream of α-1 adrenergic signaling in cardiomyocytes 
[22]. Vgll4 has no previous roles described in hES cells. For a complete description of 
Vgll4, please refer to Chapter 3. 
I chose to concentrate on Vgll4 for my characterization for two reasons. First, it 
was the only candidate that was identified multiple times in the primary screen, an 
event of very low probability that underscores a powerful effect. Second, Vgll4 is the 
only transcriptional regulator out of our positive hits. I was interested in an effect closer 
to the transcriptional network of hES cells. 
Vgll4 consistently maintained colony morphology and high levels of Oct4 after 
treatment with the combination of inhibitors (TF) (Figure 2-9). Additionally, Vgll4-
overexpressing cells maintained expression of a panel of pluripotency markers after 










Figure 2-8. Individual verification of preliminary candidates reveals positive hits for pluripotency 
maintenance. Three independent rounds of candidate verification are shown. Images show Oct4 staining 
in the samples treated with the combination of inhibitors for five days. We also included other 
pluripotency-related genes that were not originally in our list of preliminary candidates. We performed a 
qualitative evaluation of colony morphology and proportion of Oct4 expression to identify positive hits. 
Vgll4 consistently retains Oct4 expression and colony morphology. An asterisk marks the genes identified 



















Figure 2-9. Vgll4 is a co-transcriptional regulator that can maintain hES cell identity after 
treatment with inhibitors. Cells transduced with Vgll4 or control genes were treated with vehicle 
control or with the inhibitor mix for 5 days and stained for Oct4 at the end of the treatment. 
Quantification of Oct4+ cells after treatment using Cellomics image acquisition and software (DMSO: 










Figure 2-10. Vgll4 maintains expression of pluripotency markers after treatment with TGFβi 
and FGFi. Cells overexpressing Vgll4 and treated with the combination of inhibitors for 5 days are able 
to maintain expression of a panel of pluripotency markers including transcription factors Oct4, Sox2, and 
Nanog as well as surface markers like Tra 1-60. 
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B. CD99 Antigen-like 2 (CD99L2) 
CD99L2 is a paralog of the surface protein CD99. In contrast to CD99, CD99L2 is 
strongly conserved among human, rat, mouse, and zebrafish [23]. The only described 
role to date for CD99L2 is that, much like CD99, it is necessary for migration of 
leukocytes across endothelial cells during the inflammatory response [24].  
Additionally, CD99L2 is sufficient to mediate cation-dependent cell adhesion. This 
suggests a role in mediating cell adhesion in certain cell populations. 
C. Charged multivesicular body protein 4A (CHMP4A) 
CHMP4A belongs to the chromatin modifying protein/charged multivesicular 
protein family. These proteins form part of the endosomal sorting complex required for 
transport-III (ESCRT-III), which degrades surface receptor proteins and forms 
multivesicular bodies [25]. CHMP4A has been shown to have a role in membrane 
curvature and budding [26].  
D. NUAK family, SNF1-like kinase 2 (NUAK2) 
NUAK2 is a member of the SNF1/AMP family of serine/threonine kinases. This 
family of kinases is involved in sensing the energy levels in the cell and coupling that 
information with growth and proliferation [27]. Therefore, when deregulated, this gene 
can contribute to tumor progression. This family of kinases is known to be regulated by 
tumor suppressor LKB1 and by the death receptor through NF-κB [28].  Additionally, 
NUAK2 has been shown to have a role in regulating actin stress fibers, especially in 




We were interested in implementing a broad approach to discover genes involved 
in the maintenance of the pluripotent state in hES cells. To date, some screens have 
explored finding pluripotency genes in hES cells [30]. However, these have mostly 
focused on a loss-of-function approach. We designed a screen based on the inhibition of 
TGFβ signaling to identify positive hits in a genetic gain-of-function screen. Our positive 
and negative controls were validated in these conditions. We identified 75 preliminary 
candidates that were subsequently validated in a secondary assay of higher stringency. 
Four hits were identified and we decided to focus on Vgll4 given its role in transcription 
regulation. Our screen provides a proof-of-principle that gain-of-function screens using 
lentiviruses are an efficient approach to gene discovery and characterization in hES 
cells. 
Our list of primary candidates represents approximately 1% of genes contained in 
our initial library. Vgll4, the candidate that was chosen for further characterization, was 
identified three independent times in the primary screen. This is a very low probability 
event (1x10-6), suggesting a robust effect for Vgll4. In addition, Vgll4 was the only gene 
out of the 75 preliminary candidates that was identified multiple times. In the future, to 
know if one is operating close to saturation, the positive control (Nanog, in this case) 
could be included at known low quantities in the screening pool. 
Our calculations predict that the library should be represented about 1000 times, 
however, it is possible that we are still operating below saturation. This means that 
many more ORFs contained in our screened pool could have been missed as primary 
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candidates. While operating below saturation possibly allowed us to find the genes with 
the most robust effect, it would be interesting to find more primary hits. Additionally, 
since the time we carried out these experiments, the Center for Cancer Systems Biology 
Human ORFeome Consortium (Dana Farber Cancer Institute, Harvard University) has 
derived version 7.1 of the human ORFeome, containing close to 20, 000 ORFs 
representing over 15, 000 genes. If a screen were to be repeated with those larger pools 
using these same optimized conditions, many more genes with a potentially important 
role in pluripotency could be identified. 
For many genes involved in the regulation of pluripotency, expression at specific 
levels is of utmost importance. Nanog is one of the few genes that can be overexpressed 
for long periods of time without altering the pluripotent potential of hESCs [1, 11]. 
Timing is an important factor to consider when optimizing screening conditions. Our 
initial screening conditions were stringent in the sense that if a gene causes 
differentiation when overexpressed, but still has an important role in pluripotency, it 
would likely not be recovered using our conditions. For instance, levels of Oct4 and 
Sox2 need to be carefully regulated for human and mouse ES cells to remain pluripotent 
[12, 13, 31]. Therefore, one could ponder that perhaps our longer primary screening 
conditions are also selecting for genes involved with survival and overcoming stress 
under differentiation cues rather than maintaining a fine balance of gene products in 
the pluripotent state. Interestingly, some of our primary candidates seem to have a role 
in regulating apoptosis and the stress response. High levels of cell death are 
consistently observed in the first few days of hES cell differentiation. It is therefore 
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possible that by inducing differentiation, we are not only creating permissive conditions 




2.5 Materials and Methods used in this chapter 
2.5.1. Culture of hES cells 
HUES6 were plated on irradiated murine embryonic fibroblasts (MEFs) and grown 
in media containing KO-DMEM (Invitrogen), 10% Knockout Serum Replacement (KOSR, 
GIBCO), 10% human plasma fraction (Talecris), 2 mM L-glutamine (Invitrogen), 0.1 mM 
non-essential amino acids (GIBCO), .055 mM β-Mercaptoethanol (GIBCO), and 10 ng/ml 
bFGF (Invitrogen). Cultures were passaged using 0.05% Trypsin-EDTA (GIBCO) at a 
ratio of 1:6-1:10 every 5-7 days. 
Where indicated, SB-431542 (Sigma Aldrich) was used at a concentration of 10 
μM, SU-5402 (Tocris) at 20 μM. Both of these were resuspended in DMSO. DMSO vehicle 
controls were made with the equivalent volume of DMSO of the two chemicals 
combined. Retinoic Acid was used at a final concentration of 10 μM. 
MEFs were plated on plates coated with 0.1% gelatin. MEF media contained 1X 
DMEM (Mediatech), 10% FBS, 2mM L-glutamine (Invitrogen), and 0.1mM non-essential 
amino acids (GIBCO). 
2.5.2. Lentivirus production 
293T/17 cells were grown in DMEM (Mediatech), 10%FBS, 2 mM L-glutamine 
(Invitrogen), and 0.1 mM non-essential amino acids (GIBCO). A day before transfection, 
cells were plated at a concentration of  ~85000 cells/cm2  (or 8.0 x 105 per well of a 6-
well dish). 20 hours later a media change was done on the cells. 2 hours after adding 
fresh media, the cells were transfected with a total of 2 μg DNA per well of a 6-well dish. 
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A third-generation packaging system consisting of tat, rev, gag/pol and VSVG was mixed 
in a ratio of 5:1:1:1:2 (DNA:tat:rev:gag/pol:VSVG). As per manufacturer’s instructions, 5 
μl of TRANS-IT 293 (MirusBio) and 167 μl Optimem (GIBCO) were mixed thoroughly 
and incubated at room temperature for 5-10 minutes. Following this incubation, 172 μl 
of Mirus/Optimem mix was added to the DNA/packaging plasmid mix with very gentle 
mixing and incubated for 20 minutes at room temperature. After this incubation, the 
mix was added dropwise onto the cells and mixed gently by moving the plate back and 
forth. A media change was performed 24 hours later. Virus was harvested 24 hours 
later, filtered through a low-protein binding 0.45 μm filter, and added to cells or flash 
frozen in liquid nitrogen and stored at -80°C until use. 
2.5.3. hES cell transduction 
Cells were MEF-depleted for 30-45 min on gelatin-coated plates. Cells in 
suspension were collected, counted, and mixed with harvested lentivirus at an MOI of 2. 
Cells were incubated with the virus in a low-attachment dish for 2-3 hours at 37°C and 
5% CO2 with occasional rocking. After this time, the cells were pelleted by 
centrifugation at 1000 rpm for 5 minutes at room temperature. The cells were then 
plated onto Puromycin-resistant MEFs. 48 hours later, transduced cells were selected 





2.5.4. Flow cytometry analysis 
Cells treated with DMSO or 10 μM SB-431542 were harvested using 0.5% trypsin. 
Cells were washed once in PBS and then incubated in 100 μl of a 1:100 dilution of 
mouse IgM anti-Tra 1-60 (Millipore) or rat IgM anti-SSEA-3 (Santa Cruz Biotechnology) 
in FACS buffer (2% Hyclone Fetal Calf Serum in PBS). Cells were incubated in primary 
antibody for 15-30 minutes on ice. After this incubation, cells were washed with PBS 
and stained with secondary antibodies conjugated to APC (Jackson Immunoresearch) at 
a dilution of 1:300 for 15 minutes on ice. Cells were washed with PBS and resuspended 
in FACS buffer. Cells were filtered immediately before analysis through a 35 μm filter. 
An LSRII was used for analysis. 
2.5.5. Immunofluorescent staining 
Cells were washed once with PBS and fixed with 4% paraformaldehyde in PBS for 
20 minutes at room temperature. Two washes were performed after fixation. Cells were 
blocked for 1 hour at room temperature or overnight at 4°C in 5% donkey serum in 
0.1% PBST (0.1% TritonX-100 in PBS). Cells were incubated with primary antibodies in 
block for 2 hours at room temperature or overnight at 4°C. Primary antibodies used are: 
goat anti-Oct-4, 1:200 (Santa Cruz biotechnology); rabbit anti-Nanog, 1:50 (R&D); 
mouse anti-Sox2 1:200 (Cell Signaling Technologies), mouse IgM anti-Tra 1-60 
(Millipore). Primary antibody was washed 2-3 times with 0.1% PBST. Next, cells were 
incubated for 1 hour at room temperature with secondary antibodies raised in donkey 
and conjugated to Alexa fluorescent probes. All secondary antibodies were used at a 
1:300 dilution. Cell nuclei were stained using DAPI at 1 μg/ml. 
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2.6 Note regarding author contributions 
Dr. René Maehr subcloned the hORFeome library into the Gateway-optimized pHAGE 
vector. He also contributed to the design of the primary and verification screens. 
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Chapter 3  
Vgll4 is a novel regulator of survival in human 
embryonic stem cells 
3.1 Introduction 
3.1.1. Vestigial-like proteins are transcriptional co-regulators that 
mediate the activity of Transcriptional Enhancer Factors 
Vgll4 is a member of the Vestigial-like protein family, which contains four genes 
(Vgll1-4) in mice and humans. Vestigial-like proteins are transcriptional co-regulators 
that mediate the activity and determine the tissue specific gene control of 
Transcriptional Enhancer Factors (TEFs), also known as TEA domain-containing factors 
(TEADs) [1-3]. TEF/TEAD family members contain a TEA domain that allows them to 
bind DNA [4]. They regulate transcription of genes in multiple tissues, and it is thought 
that the co-transcriptional regulators they interact with confer their specificity [5]. Vgll 
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proteins contain a tondu motif (TDU), a conserved domain through which they interact 
with TEF factors. 
The Vgll family of proteins is named for the founding member of the gene family, 
the Vestigial (Vg) gene in D. melanogaster. In Drosophila, loss of Vg prevents wing 
development and interferes with cell proliferation in the precursor cells of the wing 
imaginal disc [6, 7]. This suggests that mammalian orthologs of Vg might also have a 
role in the maintenance of multipotent cell populations. 
Vgll4 is the only member of the Vgll family with two TDU motifs instead of one. 
The functional relevance of this double motif is not well understood, but some studies 
have suggested a role in bridging two transcription factors, for instance TEF-1 and MEF-
2 [1]. The function of Vgll4 remains largely unstudied apart from a described role in 
transcriptional regulation in developing cardiomyocytes. In this study, Vgll4 was shown 
to interact with MEF-2 and TEF-1 in vitro. Additionally, the authors suggest nuclear 
export as a means for regulating Vgll4 function in cardiac myocytes [1].  
3.1.2. The Rho/Rock pathway prevents the death of hES cells upon 
dissociation 
One of the differences between mouse and human ES cells is their sensitivity to 
dissociation. While mouse ES cells flourish when cultured at clonal densities, hES cells 
die as single cells [8-10]. This sensitivity to dissociation is a major roadblock for many 
applications of hES cells that require growth from single cells. In hES cells, E-cadherin 
dependent cell-to-cell contacts inhibit the function of Abr, an upstream regulator of Rac 
and Rho. Abr has Rho-GEF and Rac-GAP domains. When E-cadherin-mediated cell-to-
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cell contacts are disrupted, Abr generates a Rho-high/Rac-low state, which leads to 
activation of Rock through Rho. Rock activation results in myosin hyperactivation, 
which is manifested as membrane blebbing and results in caspase-mediated apoptosis 





3.2 Characterization of Vgll4 expression 
3.2.1. Expression of Vgll4 in hES cells 
Vgll4 was identified in our screen as a gene that was able to maintain pluripotency 
marker expression and hES cell colony morphology despite inhibition of the 
TGFβ/Activin/Nodal and FGF pathways, which have shown to be important for 
pluripotency maintenance. We first wanted to assess whether Vgll4 is normally 
expressed in hES cells and if it is specific to the pluripotent state. To this end, the 
relative expression of Vgll4 was quantified in hES cells by using real-time PCR analysis 
and immunofluorescence. Immunostaining analysis with a custom-made antibody 
(please refer to Methods section for details) revealed that Vgll4 localizes to the nucleus 
of Oct4 positive cells. Additionally, to assess expression in early differentiated 
populations, hES cells were differentiated in a three-dimensional system to form 
embryoid bodies. This analysis revealed expression of Vgll4 in hES cells and in 
differentiated populations. As a positive control, parallel quantification of Oct4 and 
Nanog, shows downregulation of these pluripotent markers upon embryoid body 
differentiation, showing a successful differentiation (Figure 3-1). The observation that 
Vgll4 increases throughout the differentiation timecourse means that it is upregulated 
upon differentiation. However, from this analysis it is not possible to determine 
whether it is upregulated in a subset of cells or throughout the entire population. Given 
that Vgll4 is a co-transcriptional regulator, its function in pluripotent and differentiated 









Figure 3-1. Vgll4 is expressed in pluripotent and differentiated cells. a) Expression of Vgll4 
relative to GAPDH in pluripotent cells (WT HUES6) and across an embryoid body (EB) differentiation 
timecourse. The days of differentiation are indicated after “d” in the X axis.  b) Immunostaining of 
Oct4 and Vgll4 in hES cells. Vgll4 is detected in the Oct4-positive and some Oct4-negative cells. c) 
Expression of Nanog relative to GAPDH in pluripotent cells and EBs. d) Expression of Oct4 relative to 
GAPDH in pluripotent cells and EBs. 
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3.2.2. Effects of Vgll4 overexpression at the global transcriptional level 
To better understand the transcriptional changes taking place in hES cells 
overexpressing Vgll4, we compared the global transcriptional profiles of wildtype (WT) 
hES cells and hES cells overexpressing Vgll4 using Illumina microarrays. Arrays were 
then analyzed using SAM (Significance Analysis of Microarrays) to find genes that were 
significantly differentially expressed between the two groups [13]. The list of significant 
genes was analyzed using GeneGO for network and gene ontology information. The first 
analysis, based on the individual gene ontology categories, revealed that genes involved 
in cellular processes including development, morphogenesis, and response to stress 
responded significantly to Vgll4 overexpression. The cell processes along with the p-
values for upregulated and downregulated genes are indicated in Table 1 (Table 3-1). 
The second analysis identified networks for the list of differentially regulated genes 
based on reported interactions. This analysis revealed a significant response in 
networks regulating apoptosis and cell adhesion (Table 3-2). In both of these tables the 
p-values represent the significance that the indicated process is affected based on the 
genes that are differentially regulated. It is worth noting that this analysis alone does 
not provide information about the overall outcome of the pathway, i.e., whether it is 
activated or inhibited. To address whether this indicated an activation or repression of 
certain pathways of interest, we assessed the change in expression of individual genes 
in these pathways. We noticed significant downregulation of genes acting as key 
positive regulators of the apoptosis pathway, for instance Caspase 9, Apoptotic Protease 
Activating Factor 1 (APAF1), some Tumor Necrotic Factor (TNF) receptors, and BCL-2-
like 1 (BCL2L1) in the Vgll4 population. We also noticed a downregulation of multiple 
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cytoskeletal genes and various regulators of the Rock pathway, such as Ras homolog 
gene family, member B (RhoB), Rho Guanine nucleotide Exchange Factor 3 (ARHGEF3, 
an activator of Rho), and Arrestin beta 1 (ARRB1, a RhoA activator and mediator of 
stress fiber formation)  (Figure 3-2). These changes are currently being verified by 
real-time PCR. The changes in these individual genes are worth noting, however, we are 
aware that in some cases the fold-change is small. Therefore from this analysis alone it 
is not possible to know whether these changes are biologically significant despite being 
numerically significant. Nevertheless, taken together, these analyses suggested a 
connection to the regulation of survival, possibly coupled with communication and 










1 system development 4.121E-3 9.859E-31 
2 anatomical structure development 8.504E-4 2.441E-30 
3 developmental process 9.794E-6 2.136E-28 
4 multicellular organismal development 6.922E-6 3.975E-28 
5 anatomical structure morphogenesis 1.921E-3 4.767E-26 
6 organ development 5.178E-4 2.115E-22 
7 vasculature development 4.849E-3 1.702E-19 
8 tissue development 2.092E-3 2.038E-18 
9 response to stress 6.062E-4 1.414E-17 
10 







Table 3-2. Functional networks with a significant response to Vgll4 overexpression in 
hES cells 
# Networks pValue (upreg) pValue (downreg) 
1 
Cell adhesion_Integrins signaling to Beta-
catenin 
5.253E-1 2.576E-05 
2 Development_Cytoskeleton biogenesis 7.800E-1 4.156E-05 
3 Development_Cartillage development 3.355E-1 3.824E-04 
4 Blood coagulation_Calpain system 5.162E-1 7.398E-04 
5 Development_Ossification_BMPs 2.705E-1 9.927E-04 
6 




Apoptosis_LIGHT, Apo-2, CD27BP, FasL, 
TWEAK, TNF-alpha signaling 
2.221E-2 2.584E-03 
8 
Cell adhesion_PAI1 signaling, PPAR-beta 















Figure 3-2. Vgll4 causes downregulation of genes involved in apoptosis and in Rho-Rock 
pathway activation. a) Graphical representation of microarray data showing the relative expression 
changes for pro-apoptotic genes in Vgll4 relative to WT hES cells. The q-values for these changes in 
expression are: Caspase 9 q = 7.29%; TNFRSF25 q = 7.67 %; TNFRSF10B q = 2.44%; APAF1 q = 
3.35%; BCL2L1 = 4.61%. b) Graphical representation of microarray data showing the relative 
expression changes for genes involved in Rho-Rock signaling in Vgll4 relative to WT hES cells. The q-
values for these changes in expression are: RHOB q = 2.34%, ARGEF3 q = 2.75%, ARRB1 q = 7.67%. 
Q-values were obtained by analysis with SAM. 
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3.3 Vgll4 overexpression results in faster doubling time of 
pluripotent cell populations 
hES cell lines transduced with Nanog, Tubulin and Vgll4 were maintained over 
multiple passages. In this maintenance, Vgll4-hES cells consistently had 2-3 fold higher 
numbers of cells at the end of each passage despite the same number of cells being 
plated at the beginning. The exponential growth formula (N = No ekt) reveals a higher 
growth rate (k) in multiple hES cell and iPS cell lines overexpressing Vgll4, indicating 
that this effect is not cell-line specific (Figure 3-3). 
The higher rate of population doubling in Vgll4-transduced cells could be 
explained through more than one mechanism. It could be due to an increase in survival, 
for instance a higher proportion of cells surviving after the initial plating or during the 
self-renewing conditions after initial plating. It could be caused by a faster replication 
rate of cells upon plating. It could be a combination of increased survival and 
proliferation. Our initial assessment of changes to cell cycle dynamics is presented in 
Chapter 4.  
Previous gene expression analyses revealed an important role for Vgll4 in the 
regulation of stress and cell death pathways as well as changes in multiple cytoskeleton 
and cell adhesion proteins, suggesting a role for Vgll4 in regulating attachment to the 
substrate and neighboring cells. Human ES cells are particularly sensitive to 
dissociation [8, 9, 11, 14], therefore, we began by exploring the question of whether 






Figure 3-3. Pluripotent cells overexpressing Vgll4 have a higher population-doubling rate in 
maintenance conditions. Graphs depicting the growth rate (k) using the exponential growth formula N 
= No ekt where N= final number of cells, No = initial number of cells, t = time after plating in days. The data 
was plotted on a log-normal scale and a linear fit was performed. a) Human embryonic stem cell lines 
overexpressing Nanog, Tubulin, or Vgll4 and maintained in self-renewing conditions. Eight timepoints 
were analyzed for HUES6, seven for HUES1, and six for HUES8. b) Human induced pluripotent stem cell 
lines overexpressing Nanog, Tubulin, or Vgll4 and maintained in self-renewing conditions. Seven 
timepoints were analyzed for iPS RBd and eight for iPS 18a. 
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3.4 Vgll4 protects pluripotent cells from dissociation stress 
3.4.1. Vgll4 maintains a higher proportion of live cells 
Disrupting cell-to-cell contact in hES cells results in myosin hyperactivation and 
apoptosis [8, 12]. Low survival of hES cells upon passaging and dissociation poses a 
difficulty for certain applications of these cells, including genetic manipulation to 
generate reporter lines and correct disease-related genetic mutations. Therefore, we set 
out to answer whether Vgll4 had a role in promoting the survival of hES cells upon 
dissociation. We took advantage of changes in membrane asymmetry and permeability 
-one of the hallmarks of apoptosis- to identify the proportion of live cells, apoptotic 
cells, and dead cells after treatment with dissociation agents.  
To disrupt cell-to-cell interactions without affecting membrane-bound proteins 
and receptors, a Hank’s-based enzyme-free dissociation buffer was used at a 1:5 
dilution with hES cell medium. As an alternative treatment, Ethylenediaminetetraacetic 
acid (EDTA) was added to hES cell medium at a concentration of 500 μM to disrupt 
Calcium-ion-dependent E-cadherin junctions. Etoposide, a topoisomerase inhibitor, is 
known to cause apoptosis by introducing double-strand DNA breaks [15, 16]. We used 
etoposide at a concentration of 10 μM a positive control for apoptosis. We expected hES 
cells to be especially sensitive to this treatment, as etoposide efficiently affects rapidly 
dividing cells [17]. Untreated cells were fed normally with hES medium. 
After 12-18 hours, both floating cells and attached cells were harvested with 
0.05% Trypsin-EDTA for 3 minutes and stained with Allophycocyanin (APC)-conjugated 
Annexin V and Propidium iodide (PI). Annexin V detects asymmetrical and 
 78 
 
compromised membranes by binding to phosphatidylserine, a phospholipid in the 
plasma membrane that localizes to the cytosolic leaflet of the plasma membrane in live 
but not apoptotic cells [18]. PI detects DNA but can only enter the cell when membranes 
are compromised, as happens in dead cells. Together, these reagents allow the 
identification of live, apoptotic, and dead cell populations by flow cytometry. A 
representative example of these results is depicted in Figure 3 (Figure 3-4). 
We found that Vgll4 had a statistically significant effect in maintaining a higher 
proportion of live cells. Vgll4 allowed the maintenance of close to 70% of live cells 
compared to the Tubulin control with approximately 50% in untreated conditions. This 
represents a 40% increase in the proportion of live cells compared to the Tubulin 
control. Additionally, Vgll4 cells maintained over 56% live cells versus 43% in Tubulin 
cells after EDTA treatment. This represents an increase of 30% in the proportion of live 
cells relative to Tubulin controls. In addition to maintaining a higher proportion of live 
cells, Vgll4 was also able to decrease the proportion of apoptotic cells in both 
conditions, with 37-53% fewer apoptotic cells. These results demonstrate a powerful 
effect in counteracting cell death caused by cell dissociation (Figure 3-5) and can 
contribute to our observation of a higher population-doubling rate. It is worth noting 
that for these analyses both floating and attached cells were assayed after treatment, 
which explains the lower proportion of live cells compared to assaying the adherent 




Interestingly, the proportion of dead cells in Vgll4 cells is consistently higher after 
treatment with etoposide. Etoposide is known to efficiently target rapidly dividing cells 
[17]. Therefore, it is possible that this is caused by an increased rate of replication in 




Figure 3-4. Annexin V and PI staining can be used to detect live, apoptotic, and dead cell 
populations in hES cells. a) Vgll4- and Tubulin-transduced hES cells either untreated or treated with 
dissociation buffer for 12-18 hours and stained with Annexin V-APC and PI, then analyzed by FACS. 
Live cells are APC-, PI-; apoptotic cells are APC+, PI-, and dead cells are PI+. b) Etoposide (ETO)-treated 







Figure 3-5. Vgll4 promotes survival and inhibits apoptosis in response to cell 
dissociation. hES cells overexpressing Vgll4 or Tubulin were treated with a Hank’s-based enzyme-
free dissociation buffer or 500 μM EDTA or 10 μM etoposide (ETO) for 12-18 hours. The proportion 
of live, apoptotic, and dead cells was assessed by Annexin V and PI staining. Results represent flow 
cytometry data from 6 independent experiments. Error bars represent the standard deviation and the 




3.4.2. Vgll4 suppresses Caspase activity 
We wanted to assess whether the increased proportion of live cells and decreased 
proportion of apoptotic cells in Vgll4-transduced cells resulted from a decrease in 
caspase activity. Caspase-9 is an initiatior caspase that associates with APAF-1 to form 
the apoptosome complex, which activates effector caspases. Caspases 3 and 7 are 
effector caspases that cleave multiple substrates, leading to apoptosis and eventually 
cell death [19-21]. 
Following the same treatment explained above we used a luminescence-based 
assay to assess Caspase-3/7 and Caspase-9 activity. This assay uses a proluminescent 
caspase substrate that serves as a substrate for luciferase upon cleavage by caspases. 
Vgll4-hES cells showed a significant decrease in activated Caspase-3/7 and 9 activity in 
both the untreated and dissociation conditions (Figure 3-6). This suggests that Vgll4-
hES cells have a lower basal activation of caspases, perhaps resulting in a protective 









Figure 3-6. Vgll4 decreases Caspase 3/7 and Caspase 9 activity. a) Caspase 3/7 and b) 
Caspase 9 activity for Vgll4- and Tubulin-hES cells after treatment with dissociation conditions. Both 
were assessed using caspase luminescence assays. Relative luminescence units (RLU) represent the 
signal after subtracting the background. Background was obtained by mixing medium with assay 
buffer. Error bars represent the standard deviation of triplicates. P-values were obtained using an 
unpaired Student’s T-test. 
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3.4.3. Vgll4 is necessary to regulate survival and caspase activity of 
hES cells 
A. Identification of an shRNA against Vgll4 
We wanted to test whether Vgll4 was necessary to regulate survival in hES cells. 
To this end, single-stranded oligonucleotides were obtained from the Invitrogen 
database and annealed as instructed. The hairpins were then cloned into the same 
pHAGE vector used for the rest of our stably transduced lines and the population of 
cells that was successfully transduced was selected using puromycin. We identified a 
short-hairpin RNA (shRNA) against Vgll4, referred to as V78. Transduction of hES cells 
with V78 resulted in a 60% knockdown of Vgll4 compared with cells transduced with a 
scrambled control (mir neg) as assessed by real-time PCR (Figure 3-7). We are 
currently optimizing conditions for the Western Blot verification of these results. 
 
Figure 3-7. V78 is a shRNA that achieves 60% knockdown of Vgll4. Vgll4 expression levels 
relative to GAPDH in cells transduced with a shRNA against Vgll4 (V78) or a scrambled control (mir 
neg). V78-1 A and B represent different virus production batches and transductions. 
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B. Assessment of live cell proportion and Caspase activity 
Cells stably expressing a scrambled control (mir neg), V78, or Vgll4 itself were 
treated with the dissociation conditions described earlier. Annexin V and PI staining 
were used to assess the proportion of live, apoptotic, and dead cells in these 
populations. We found that knockdown of Vgll4 increased the proportion of dead and 
apoptotic cells and decreased the proportion of live cells. This effect was especially 
noticeable under dissociation conditions (Figure 3-8). Our statistical analysis identified 
a significant difference when V78 cells were compared to Vgll4 but not mir neg. One 
explanation for this finding is that the change in proportions is not numerically 
significant; however, this could still have a biological effect, albeit subtle. The second 
possibility is that there is still enough residual Vgll4 activity and a stronger knockdown 
of is necessary to observe a significant change. Additionally, using the different assays 
we have introduced earlier should give a more complete picture for the consequences 
of decreased Vgll4 levels. For instance, we are currently testing the effect of Vgll4 
knockdown in population-doubling rate and colony-forming ability. 
We also tested whether knockdown of Vgll4 would affect Caspase activity. For this 
purpose, we treated cells with dissociation conditions and assessed the activation of 
Caspase 3/7 and Caspase 9 with a luminescence-based assay. V78 caused a small but 
statistically significant increase in Caspase 3/7 and 9 activities under dissociation 












Figure 3-8. Vgll4 knockdown increases hES cell sensitivity to dissociation conditions. hES 
cells stably expressing a scrambled control (mir neg), V78, or Vgll4 were treated with a Hank’s-based 
enzyme-free dissociation buffer, 500 μM EDTA or 10 μM etoposide (ETO) for 12-18 hours. The 
proportion of live, apoptotic, and dead cells was assessed by Annexin V and PI staining. Results 
represent flow cytometry data from 3 independent experiments. Error bars represent the standard 







Figure 3-9. Vgll4 knockdown increases caspase activity upon treatment with dissociation 
conditions. a) Caspase 3/7 and b) Caspase 9 activity for mir neg, V78, and Vgll4-hES cells after 
treatment with dissociation conditions. Both were assessed using Caspase-Glo luminescence assays. 
Relative luminescence units (RLU) represent the signal after subtracting the background. Error bars 




3.5 Vgll4 confers an advantage in colony forming potential 
from single cells 
The colony-formation assay has historically been used as a test for self-renewal of 
multipotent progenitors. In the case of hES cells, it is also a stringent assay for survival 
in response to dissociation. We wanted to directly test the ability of Vgll4-hES cells to 
form colonies after dissociation into single cells. Nanog, GFP, and Vgll4-hES cells were 
dissociated using 0.05% Trypsin-EDTA for 3 minutes at room temperature and 1000, 
100, 10 or 1 cell per well were sorted using FACS onto 96-well plates using an antibody 
recognizing Tra1-60 as a marker to selectively sort out only pluripotent cells. After 10 
days, the cells were fixed, stained for DAPI and scored for the presence or absence of a 
colony in a well. Vgll4 increases hES cell colony-forming efficiency by 2-3 fold in the 
presence and absence of Rock-inhibitor (Figure 3-10). We observed a consistent 
increase in the colony forming ability of Vgll4 cells. However, the variance in the 
number of colonies prevented us from performing statistical analysis.  
In addition, to assess whether the clonally-derived cells had remained 
undifferentiated during the 10 days in culture. To this end, colonies were stained with 
pluripotency markers. In addition, the cells retained expression of the lentiviral gene as 














Figure 3-10. Vgll4 increases the colony-forming efficiency of hES cells. a) hESCs transduced 
with Nanog, GFP or Vgll4 were plated at single cell densities on 96-well plates and counted 10 days 
after plating. Percentage of wells where colonies formed is shown for conditions with and without 
Rock inhibitor. b) Results for low-density plating at 1000, 100, 10 and 1 cells per well. Errors bars 




Figure 3-11. Clonally-derived cells maintain expression of pluripotency markers and 
lentiviral genes. After 10 days in culture, colonies derived from single cells were fixed and analyzed 




3.6 A possible interaction between Vgll4 and the Rho/Rock 
pathway for promoting hES cell survival 
Finally we addressed whether the activity of Vgll4 was required for the beneficial 
effects of Rock inhibition on hES cell survival. A dose-response curve for Rock inhibition 
showed an increased colony forming efficiency at increasing concentrations of the 
inhibitor with a plateau reached at concentrations between 6-10 μM (Figure 3-12 a). 
We next compared the effect of increasing concentrations of the inhibitor on cells 
deficient for Vgll4 using hES cells transduced with V78. No significant differences were 
detected between control and knock-down cells in a colony forming assay either in the 
absence of Rock inhibitor or at high concentrations of the inhibitor. However, at 
intermediate concentrations of Rock inhibitor (1 μM-7.5 μM), we observed that cells 
deficient for Vgll4 have a decreased colony-forming efficiency compared to wildtype 
cells (Figure 3-12 b,c). These results demonstrate that Vgll4 may be necessary to fully 
benefit from the inhibition of Rock activity, therefore implying a possible genetic 






Figure 3-12. A possible interaction between Vgll4 and the Rho/Rock pathway promotes 
survival of hES cells. Colony formation efficiency for 100 cells/well treated with the indicated 
concentrations of Rock inhibitor. a) Rock inhibitor dosage response curve in control cells (mir neg). b) 
Colony formation efficiency of control (mir neg) and Vgll4-knock-down (V78) cells. V78 are deficient in 
their colony-forming ability. c) Full Vgll4 functionality is required to benefit from Rock-inhibition. V78 
colony-forming efficiency is shown normalized to the colony-forming efficiency of mir neg. Increasing 
concentrations of Rock inhibitor are unable to rescue for Vgll4-deficiency at non-saturating 
concentrations. d) Model for mode of action of Vgll4. Rho signaling is activated upon disruption of E-
cadherin cell-to-cell contacts resulting in apoptosis. Vgll4 could inhibit cell death by modulating the 
expression of apoptosis and cytoskeleton genes. Alternatively, VGLL4 could have a role in the cytoplasm 






3.7 Conclusions and Discussion 
Vgll4 has not been described previously in the context of hES cells. Our findings 
identify Vgll4 as a novel gene promoting the survival of hES cells in response to 
dissociation. Its pro-survival activity has important implications for overcoming the 
problem of low survival of hES cells in clonal densities, which would greatly facilitate 
the derivation of reporter lines and the ability to correct disease-related mutations. 
Both of these would represent a step forward in disease-modeling and therapy using 
pluripotent cells. 
Interestingly, Vgll4 is expressed in both self-renewing hES cells and differentiated 
cells. Nevertheless, the specificity of its activity in pluripotent cells could be dictated by 
two factors: 1) the specific transcription factors present at each cell stage, thus leading 
to regulation of a different set of genes in hES cells versus differentiated cells, and 2) the 
particular characteristics, such as the transcriptome and the epigenome of each cell 
type. For instance, sensitivity to dissociation is an important consideration for hES cells 
but not for other cell populations tested such as normal human dermal fibroblasts and 
human vascular endothelial cells. 
Global transcriptional analysis in hES cells revealed significant differences in 
cellular processes including organogenesis and response to stress through the 
modulation of apoptosis and cytoskeletal genes in cells transduced with Vgll4. Together 
with our Annexin V/PI data, this suggests that Vgll4 is a mediator of apoptosis. Given 
the current understanding of the role of dissociation and its connection to the myosin 
cytoskeleton and hES cell apoptosis [8, 14], this could suggest a link between changes to 
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cytoskeleton genes and increased survival in Vgll4 cells. For instance, Vgll4 could have a 
role in allowing hES cells to attach more efficiently to the substrate or neighboring cells 
through cytoskeletal changes while inhibiting members of the apoptosis pathway that 
unleash a cell death response. A lower rate of cell death in response to dissociation 
could also contribute to the faster population-doubling rate that we observed in 
multiple pluripotent cell lines. It is important to note that Vgll4 is a complex gene with 
multiple predicted splice variants. Therefore, it is possible that it could also modulate 
other mechanisms that contribute to this observation, for instance, cell cycle dynamics. 
We initially hypothesized that the observed increase in the rate of population-doubling 
was due to an increase in cell proliferation. Our initial experiments, presented in 
Chapter 4, show no difference in the distribution of cells in the cell cycle or in the 
proportion of mitotic cells. We refer the reader to Chapter 4 for an explanation of our 
future directions in testing for changes to the cell cycle. The expression pattern and 
function of the different splice variants is currently not known. The ORF contained in 
the human ORFeome represents isoform a, which has the longest transcript and gives 
rise to the longest protein. 
Our results show that Vgll4 functionally contributes to an increase in the 
proportion of live cells and a decrease in the proportion of apoptotic cells in untreated 
conditions and after dissociation treatment. These observations could be explained, at 
least in part, by a decreased activity of initiator and effector caspases. These results 
could have functional and therapeutic relevance for improving maintenance and 
subcloning strategies for pluripotent stem cells. To evaluate if the increase in 
proportion of live cells in untreated conditions is enough to explain the difference in 
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doubling time, it would be possible to explore the differences in cell number early after 
plating. This assay is currently in progress. 
A decrease in Vgll4 levels resulted in an increase in apoptotic cells and a decrease 
in live cells, as well as an increase in caspase activity under dissociation conditions, 
indicating a necessary role for regulating caspase activation upon dissociation stress. 
However, the effect of knockdown of Vgll4 on the levels of activated Caspases was 
smaller than expected in untreated conditions. This might also explain the absence of a 
significant change in the proportion of Annexin V and PI-positive populations in 
untreated conditions. Some explanations for this observation include the fact that this is 
a mild knockdown; effect of Vgll4 downregulation could be more significant with a 
more complete knockdown but we were unable to identify a shRNA that led to a more 
than 60% reduction in the levels of Vgll4 RNA. A second explanation is that redundancy 
is likely to exist in the regulation of cell survival. Many mechanisms and pathways 
orchestrate the decision of whether a cell lives or dies. It is possible that other members 
of this pathway can rescue the absence of one gene. For this reason, finding an effect 
through a gain-of-function approach is more feasible than through a loss-of-function 
approach. A third explanation is that specific conditions are needed to unmask the Vgll4 
knock-down phenotype. For this purpose, we tested the colony-formation efficiency of 
Vgll4-deficient hES cells at increasing concentrations of Rock inhibitor and found that 
these cells were impaired in their colony-forming ability. This result implies that 
normal Vgll4 levels are required to benefit from the effect of Rock inhibitor and suggest 
an interaction between these pathways to promote hES cell survival. 
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The discovery of Rock inhibitor and its ability to increase the survival of 
dissociated hES cells provided an important tool to begin to address the problem of low 
viability of hES cells upon dissociation [9]. However, survival remains a challenge for 
many applications of pluripotent cells. Importantly, Vgll4 is able to increase the colony-
forming ability of single hES cells by 2-3 fold in the presence and absence of Rock 
inhibitor. Given that Vgll4 is a co-transcriptional regulator, we hypothesize that Vgll4 
may act in the nucleus to mediate transcriptional changes that prevent activation of 
apoptosis. Alternatively, Vgll4 could be exported out of the nucleus to carry out a 
transcription-independent role for modulating cell survival, perhaps by directly 
interacting with members of the Rock pathway in the cytoplasm (Figure 3-12 d). 
Therefore, this study contributes to a deeper understanding of the mechanisms 
controlling cell death and represents a possibility to uncover new chemicals to make 




3.8 Methods used in this chapter 
3.8.1. Culture of hES cells 
HUES and iPS lines were plated on irradiated murine embryonic fibroblasts 
(MEFs) and grown in media containing KO-DMEM (Invitrogen), 10% Knockout Serum 
Replacement (KOSR, GIBCO), 10% human plasma fraction (Talecris), 2 mM L-glutamine 
(Invitrogen), 0.1 mM non-essential amino acids (GIBCO), .055 mM β-Mercaptoethanol 
(GIBCO), and 10 ng/ml bFGF (Invitrogen). Cultures were passaged using 0.05% 
Trypsin-EDTA (GIBCO) at a ratio of 1:6-1:10 every 5-7 days. 
MEFs were plated on plates coated with 0.1% gelatin. MEF media contained 1X 
DMEM (Mediatech), 10% FBS, 2mM L-glutamine (Invitrogen), and 0.1mM non-essential 
amino acids (GIBCO). 
3.8.2. Embryoid body differentiation 
hESCs transduced with the indicated genes were gently trypsinized and placed in a 
low-attachment 6-well dish at a concentration of 1x106 cells/well in hES cell medium 
without bFGF. Cells were left undisturbed for the first 96 hours to allow for formation of 
individual EBs and media was changed every 48 hours thereafter. A fraction of EBs 
were collected at the indicated times and used as a source of RNA. 
3.8.3. Real-time PCR analysis 
RNA was harvested using a Qiagen RNeasy kit. DNAse I treatment was used as 
indicated by the manufacturer to eliminate genomic DNA. Purified RNA was used as 
input for the reverse transcription reaction using the Superscript III First Strand kit 
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(Invitrogen). TaqMan assays (Applied Biosystems) were used for the following human 
genes and samples were prepared following manufacturer instructions: POU5F1, 
NANOG, VGLL4. GAPDH was used as a control. All samples were analyzed using a 
7900HT machine (Applied Biosystems) using the Fast protocol as specified by the 
manufacturer (Applied Biosystems). Cycling parameters were the following: UNG 
incubation, 2 minutes at 50°C; Polymerase activation, 20 seconds at 95°C; denaturing, 1 
second at 95°C; anneal/extend, 20 seconds at 60°C with 40 cycles of 
denaturing/extending/annealing. Resulting Ct values were then processed using the 
ΔΔCt method to obtain relative changes in expression.  
3.8.4. Microarray analysis 
RNA was purified from samples in quadruplicates (biological replicates) using a 
Qiagen RNeasy kit and 200 ng of starting material were used as input for the Illumina 
TotalPrep Amplification Kit. Samples were then hybridized to an Illumina microarray. A 
selection of genes with a p-value < 0.05 on at least 5 arrays was analyzed using SAM 
(http://www-stat.stanford.edu/~tibs/SAM) with an FDR=7%. Network and gene 
ontology analyses were performed using GeneGO (http://www.genego.com). 
3.8.5. Growth curve analysis 
Cells were passaged as described above. An aliquot of cell suspension was counted 
using a Vi-Cell XR counter (Beckman Coulter).  The exponential growth formula (N = 




3.8.6. Apoptosis analysis by Annexin V and PI 
Cells were treated with a mixture of Enzyme-free dissociation buffer (Millipore) 
and hES medium at a ratio of 1:5, 500 μM EDTA, or 10 μM etoposide for 18 hours at 
37°C and 5% CO2. All floating cells were collected. Remaining adherent cells were then 
trypsinized and washed with ice cold PBS. Cells were stained following manufacturer 
instructions (Invitrogen) as follows. First, cells were resuspended in Annexin V binding 
buffer and aliquoted where necessary to have 1-2 x 106 cells per sample of 100 μl. Cells 
were then stained with 1 μg/ml PI and 5 μl of APC Annexin V. Samples were incubated 
at room temperature for 15 minutes protected from light. After the incubation period, 
cells were resuspended in 400 μl of binding buffer and analyzed by FACS in a BD LSR II 
machine. Unstained and single-color controls were used to perform compensation and 
set gates. 
3.8.7. shRNA knockdown 
ssDNA oligos were obtained from Invitrogen for Vgll4 (V76: Hmi423276; V77: 
Hmi423277; V78: Hmi423278) and processed using the instructions for the BLOCK-iT 
Pol II miR RNAi Expression Vector Kits. shRNAs were cloned into the EF1α-pDEST using 
Gateway cloning to use the same vector used in our screening strategy. Sequences were 
verified using Geneious. Lentiviral particles were made as outlined in Chapter 2. Cells 
were transduced with the lentiviral shRNA constructs as indicated in the transduction 
section and selected with puromycin. Cells were maintained in hESC medium for 7 days 
after selection. After this timepoint cells were collected for RNA analysis or maintained 
as described above for subsequent analyses. 
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3.8.8. hES cell transduction 
Cells were MEF-depleted for 30-45 min on gelatin-coated plates as described 
previously. Cells were then counted and mixed with harvested lentivirus at an MOI of 2. 
Cells were incubated with the virus in a low-attachment dish for 2-3 hours at 37°C and 
5% CO2 with occasional rocking. After this time, the cells were pelleted by 
centrifugation at 1000 rpm for 5 minutes at room temperature. The cells were then 
plated onto Puromycin-resistant MEFs. 48 hours later, transduced cells were selected 
with 2 μg/ml of puromicyn for 2 days, generating a population of >98% transduced 
cells. 
3.8.9. Clonality assay 
Cells were dissociated with 0.05% Trypsin-EDTA as described above for 
passaging. Cells were washed once in PBS and then incubated in 100 μl of a 1:100 
dilution of mouse IgM anti-Tra 1-60 (Millipore) or rat IgM anti-SSEA-3 (Santa Cruz 
Biotechnology) in FACS buffer (2% Hyclone Fetal Calf Serum in PBS). Cells were 
incubated in primary antibody for 15-30 minutes on ice. After this incubation, cells 
were washed with PBS and stained with secondary antibodies conjugated to APC 
(Jackson Immunoresearch) at a dilution of 1:300 for 15 minutes on ice. Cells were 
washed with PBS and resuspended in FACS buffer. Cells were filtered immediately 
before sorting through a 35 μm filter. A BD Aria was used for sorting. Cells were sorted 
onto 96-well plates previously coated with BD Matrigel for hESCs and containing 100 μl 
of MEF-conditioned media supplemented with 16 ng/ml of bFGF. As indicated, 1000, 
100, 10, or 1 cell per well were plated. Rock inhibitor was used in the indicated wells at 
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a final concentration of 10 μM.  Media was changed every third day. After 10 days, cells 
were fixed with 4% PFA and stained with DAPI at 1μg/ml. Each well was inspected for 
the presence of colonies. A 4-cell minimum was considered for calling a colony. 
Immunofluorescence was performed on positive wells using a goat anti-Oct4 or a rabbit 
anti-HA as described below. 
3.8.10. Immunofluorescent staining 
Cells were washed once with PBS and fixed with 4% paraformaldehyde in PBS for 
20 minutes at room temperature. Two washes were performed after fixation. Cells were 
blocked for 1 hour at room temperature or overnight at 4°C in 5% donkey serum in 
0.1% PBST (0.1% TritonX-100 in PBS). Cells were incubated with primary antibodies in 
block for 2 hours at room temperature or overnight at 4°C. Primary antibodies used are: 
goat anti-Oct-4, 1:200 (Santa Cruz biotechnology); rabbit anti-HA, 1:50 (Cell Signaling 
Technologies); rabbit anti-Vgll4 1:50 (Genescript, custom made). Primary antibody was 
washed 2-3 times with 0.1% PBST. Next, cells were incubated for 1 hour at room 
temperature with secondary antibodies raised in donkey and conjugated to Alexa 
fluorescent probes. All secondary antibodies were used at a 1:300 dilution. Cell nuclei 




3.8.11. Vgll4 custom-made antibody 
An anti-human Vgll4 antibody was produced by Genescript. Rabbits were 
immunized with the following peptide: TANGDCRRDPRERSRSPIER. Antibody was 
validated by co-localization of HA staining and Vgll4 staining in fibroblasts transduced 
with Vgll4 lentivirus. 
3.8.12. Luminescence assays for caspase activity 
Cells were treated as described for the Annexin V/PI analysis. 15 thousand cells 
were collected for Caspase activity analysis. Caspase-Glo Assays (Promega) for Caspase 
3/7 and Caspase 9 were used following manufacturer instructions. Caspase activity was 
measured using a luminometer optimized for measuring luciferase activity. 
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3.9 Note regarding author contributions 
Dr. Julie Sneddon performed the analysis of microarray data with SAM to identify a 
list of significantly differentially expressed genes in Vgll4-hES cells.  
Dr. José Rivera-Feliciano was instrumental for the design and interpretation of the 
experiments to determine an interaction between Vgll4 and Rho/Rock signaling. 
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Chapter 4  
Elucidating the role of Vgll4 in human 





The function of Vgll4 remains largely unknown in mammalian cells. To 
characterize the mechanism of action of Vgll4, we explored several avenues in addition 
to a role in regulating apoptosis, as covered in Chapter 3. Ultimately, we chose to 
concentrate on characterizing the role of Vgll4 in survival of hES cells, however, several 
interesting leads explained in this chapter suggest that the role of Vgll4 is likely to be 
complex and include several pathways and modes of action. 
 105 
 
4.2 A role for Vgll4 in the pluripotency network 
4.2.1. Rationale 
Vgll4 was identified in a gain-of-function genetic screen for genes that could 
maintain pluripotent cell identity under inhibition of TGFβ/Activin/Nodal and FGF 
signaling –two pathways important for the maintenance of the hES cell state. Therefore, 
we tested the possibility of Vgll4 as a novel member of the pluripotency and self-
renewal network in hES cells. 
4.2.2. Results 
A. Timecourse of pluripotency marker expression 
We began by exploring whether Vgll4 could overcome long-term TGFβ inhibition 
with SB-431542 in hES cells. To this end, we quantified the expression of pluripotency 
markers Tra1-60 and SSEA-3 in cells treated with DMSO (vehicle control) or 10 μM SB-
431542. We compared Vgll4-hES cells to WT hES cells as well as hES cells transduced 
with Nanog or GFP (Figure 4-1). Vgll4 was able to maintain higher proportions of 
pluripotent cells compared to WT and GFP. However, it was not sufficient to completely 
protect from differentiation, as in the case of Nanog.  
This result could have several interpretations: 1) Vgll4 protects against 
differentiation but cannot fully halt it. Therefore, this results in a delay in 
differentiation, 2) high expression levels of Vgll4 for extended periods of time are 
deleterious to the pluripotent state. However, this second possibility is disproved by the 
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ability to maintainVgll4-hES cells in self-renewing conditions for over 15 passages 
without loss of hES cell characteristics. 
To test if Vgll4 was causing a delay in differentiation, we studied the dynamics of 
changes to colony morphology in cells treated with the combination of inhibitors for 
TGFβ and FGF (TF). We observed a noticeable difference in the loss of hES cell colony 
morphology between Vgll4-hES cells and WT hES cells (Figure 4-2). At 5 days of 
treatment with TF, Vgll4-hES cells maintained the characteristic hES cell colony 
morphology with bright edges. By this timepoint, the majority of WT hES cells had lost 
colony morphology and differentiated. We remind the reader that these were the 
conditions used for the secondary verification assay of candidate genes (Chapter 2). 
Interestingly, in that assay we looked for candidates after 5 days of TF treatment and 
found Vgll4. Therefore, our results confirmed Vgll4 as a gene that can maintain colony 
morphology and pluripotency marker expression after 5 days of TF treatment. 
However, this ability of Vgll4 to maintain hES cell morphology was lost after 2 
additional days of treatment. By Day 7 of treatment with TF, colony morphology had 
also been lost in most of the Vgll4 population. 
We wondered if Vgll4 could also delay the loss of pluripotency markers under 
other differentiation conditions. Embryoid bodies formed from aggregates of ES cells 
recapitulate many events in early embryonic development [1]. For this reason, we 
aggregated cells to form embryoid bodies and assayed for changes in the mRNA levels 
of pluripotency markers Oct4 and Nanog for a period of 15 days. 
EBs overexpressing Vgll4 were able to maintain levels of Oct4 and Nanog similar 
to those found in undifferentiated hES cells for approximately 2 days later into 
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differentiation than EBs expressing GFP or WT EBs. However the expression of these 
pluripotency markers was downregulated after this timepoint. Nanog EBs, in contrast, 














Figure 4-1. Vgll4 delays the loss of pluripotency markers in response to long-term 
treatment with SB-431542. Human ES cells were treated with SB-431542 (TGFβi) at 10μM for the 
number of passages indicated and assayed for the expression of pluripotency markers by flow 
cytometry. a) Expression of Tra1-60 over time. b) Expression of SSEA-3 over time. These results 










Figure 4-2. Vgll4 delays loss of colony morphology upon inhibition of TGFβ and FGF 
signaling. Cells were treated with 10 μM SB-431542 and 20 μM SU-5402 (TF) for 7 days. Changes in 
colony morphology were monitored for Vgll4-hES cells and WT hES cells by light microscopy. 
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Finally, we tested whether Vgll4 would have a protective effect against 
differentiation in the presence of established differentiation protocols, for instance 
those used for directed differentiation of hES cells into definitive endoderm or 
mesoderm. When hES cells were differentiated into endoderm or cardiac progenitors, 
Oct4-positive cells were almost completely lost in all cell lines, including Nanog (Figure 
4-4). Additionally, there was no difference in the induction of endoderm markers Sox17 
and FoxA2 in the presence of Nanog, Vgll4, or GFP overexpression (Figure 4-5). This 
suggests that certain treatments override the ability to maintain pluripotency markers 












Figure 4-3. Vgll4 delays the loss of pluripotency markers during embryoid body 
differentiation. Embryoid bodies were formed from WT hES cells or hES cells transduced with Nanog, 
Vgll4, or GFP. mRNA levels of a) Oct4 and b) Nanog were assessed by real time PCR throughout a 
timecourse of 15 days. Levels of expression are relative to a GAPDH control. The blue bar represents 
endogenous expression of the gene in wildtype hES cells.  P-values were calculated from Ct values using 














Figure 4-4. Overexpression of Nanog or Vgll4 is not sufficient to prevent the loss of Oct4 
expression under directed differentiation protocols. Human ES cells overexpressing Nanog, Vgll4 
or GFP were subjected to differentiation into a) endoderm or b) cardiac mesoderm progenitors. Oct4 










Figure 4-5. Human ES cells overexpressing Vgll4, Nanog, or GFP give rise to endoderm 
progenitors at similar efficiencies. Human ES cell lines were treated to induce differentiation into 




Our observations in response to treatment with inhibitors and EB formation, 
suggest that Vgll4 might have a protective effect against the loss of pluripotency 
markers, but our observations also show that some differentiation conditions might 
override overexpression of Vgll4 and even Nanog.  Next, we also wanted to assess 
whether Vgll4 affected pluripotency, the ability of cells to differentiate into derivatives 
of the three germ layers. To this end, we examined whether hES cells overexpressing 
Nanog, Vgll4, or GFP would be able to form teratomas with cells from all germ layers. 3 
x 106 to 1 x 107 hES cells overexpressing Nanog, GFP or Vgll4 were injected under the 
kidney capsule of SCID-Beige mice. Teratomas were isolated, embedded in paraffin, and 
sectioned after 40 days. We did not observe a difference in the frequency of teratoma 
formation between the different lines, but we noticed a difference in the size of the 
teratomas. Teratomas from Vgll4-hES cells were 2-3 times larger than those from 
Nanog or GFP hES cells. In all cases, we observed derivatives from the three germ layers 
(Figure 4-6). We attempted to detect the HA tag by immunofluorescence and 
expression of GFP but were unsuccessful in our attempts to optimize our staining 
protocols. Therefore we were not able to assess whether lentiviral expression was 
silenced throughout this process. Our observations allow us to conclude that 












Figure 4-6. Nanog, Vgll4 or GFP overexpression are permissive to differentiation into the 
three germ layers by teratoma formation. Human ES cells overexpressing Nanog, Vgll4, or GFP 
were injected subcutaneously into immunocompromised mice. Derivatives from the three germ 
layers were identified by hematoxylin/eosin staining. Gl: glandular epithelium (endoderm), Gt: gut-




B. Vgll4 and the master pluripotency transcription factors 
Our results showed that overexpression of Vgll4 seemed able to delay the 
downregulation of pluripotency markers. Therefore, we tested whether downregulating 
Vgll4 had an effect on the expression of pluripotency factors Oct4 and Nanog. We made 
use of V78, the shRNA against Vgll4 introduced in Chapter 3. V78 achieves a 60% 
reduction in the levels of Vgll4 by real-time PCR. In cells where the level of Vgll4 has 
been reduced, the levels of Nanog were decreased by 40%. In addition, the level of Oct4 
also decreased by 40% in some cases (Figure 4-7). 
Conversely, to test whether changes in the levels of pluripotency genes would 
affect Vgll4 expression, we tested several shRNAs against Nanog, referred to as N52-1, 
N52-2, N53-1, N53-2, N55-1, and N55-2. These hairpins achieved a reduction in the 
level of Nanog mRNA of 30-80%. In most cases, a reduction in Nanog levels correlated 
 
Figure 4-7. Expression levels of pluripotency factors respond to Vgll4 downregulation. 
The levels of Vgll4 were reduced by approximately 60% using V78, a shRNA against Vgll4. Nanog and 
Oct4 expression were assessed by real-time PCR. a) Nanog mRNA levels in cells treated with a 
scrambled control (mir neg) or V78. b) Oct4 mRNA levels in cells treated with a scrambled control 
(mir neg) or V78. A and B represent two independent virual production rounds and transductions. P-
values were calculated from Ct values using an unpaired Student’s T-test. 
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with an increase in the levels of Vgll4. This could suggest the existence of a negative 
feedback loop where Nanog is induced by Vgll4 and Vgll4 is inhibited by Nanog (Figure 
4-8). A similar inverse correlation was observed previously (Chapter 3, Figure 1) where 
Nanog was reduced by allowing cells to differentiate in EB formation, and levels of Vgll4 
concomitantly increased. It is also possible that levels of Vgll4 increase simply due to 
differentiation. Therefore, distinguishing between a direct and indirect effect in the 
regulation of Vgll4 by pluripotency genes still remains open to investigation. 
Interestingly, some indications in the literature suggest that the regulation of Vgll4 
by pluripotency genes might be direct. For instance, the Vgll4 promoter region has been 
reported to be bound by Oct4, Sox2, and Nanog in mouse ES cells through ChIP-seq 
analysis [2]. Data from this study also shows that the Vgll4 promoter harbors 
dimethylation at lysine 79 in histone H3 (H3K79me2), an epigenetic mark associated 
with active expression. However, this study also reports that the Vgll4 promoter is 
bound by Tcf3, commonly but not always associated with repression [3]. Determining 
whether Vgll4 is expressed in mES cells would be helpful to resolve whether Vgll4 is 
positively or negatively regulated by the pluripotency genes in ES cells. This 
information would be informative towards establishing a model for the regulation of 










Figure 4-8. Downregulation of Nanog levels lead to an increase in Vgll4 expression. a) 
shRNAs (N52, N53, N55) against Nanog achieve 30-80% reduction in Nanog mRNA levels. b) Levels 
of Vgll4 were assessed in response to Nanog knockdown with the indicated shRNAs. 
 119 
 
C. Reprogramming into iPS cells 
Reprogramming of adult cells into the embryonic stem cell state can be achieved 
by the overexpression of some of the core pluripotency transcription factors, including 
Oct4, Sox2, and Nanog [4-8]. Many advances have been made for improving the 
efficiency of this process [9].  
Our results have shown that Vgll4 regulates the survival of pluripotent cells and 
may delay differentiation. In addition, Vgll4 might also reinforce Nanog expression. For 
these reasons, we were interested in determining whether Vgll4 had a role in 
reprogramming. We tested whether Vgll4 would affect the efficiency of reprogramming 
together with the reprogramming factors Oct4, Sox2, and Klf4. Human fibroblasts from 
narcoleptic patients (obtained from Dr. Florian Merkle, Eggan Lab, Harvard University) 
were transduced with retroviruses for the human genes Oct4, Sox2, and Klf4. In 
addition GFP or Vgll4 lentivirus was added. In two independent attempts, we observed 
that the efficiency of reprogramming was lowered upon Vgll4 overexpression. This 
result could have several interpretations. First, that Vgll4 acts as an inhibitor of 
reprogramming. This could result from inhibiting a pathway necessary for 
reprogramming or from activating pathways that stabilize the current cell state and 
make the necessary cell changes for reprogramming more difficult.  
We certainly think that further study of this question is necessary. This 
experiment was mostly exploratory and several conditions should be optimized to get a 
strong conclusion. For instance, it would be ideal to repeat this experiment using WT 
human fibroblasts. Even though cells with multiple disease backgrounds have been 
reprogrammed, cells from narcoleptic fibroblasts could harbor important differences in 
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their reprogramming kinetics and mechanisms. Second, a careful tabulation of the 
number of resulting colonies is necessary to determine the effect to reprogramming 
efficiency. Finally, exploring the timing of Vgll4 expression would be interesting to 






We found Vgll4 in a screen designed to uncover genes important for hES cell 
maintenance. However, our results show that, unlike Nanog, Vgll4 overexpression is not 
sufficient to prevent the loss of pluripotency markers and differentiation upon 
extended exposure to differentiation inducers. Nanog has been shown to overcome 
differentiation-inducing conditions such as feeder-free growth, to maintain the 
pluripotent state in hES cells [10]. In our assays (long-term TGFβ inhibition and EB 
formation) Nanog overexpression is able to maintain expression of pluripotency 
markers Tra 1-60, SSEA-3, and Oct4. One possible explanation is that in the TGFβ 
timecourse, Nanog can overcome differentiation since it has been shown to be a 
downstream target of TGFβ signaling in hESCs, thus counteracting the effect of the 
inhibition [11]. Additionally, it is possible that we detect Oct4 expression because its 
expression is regulated by Nanog as part of a feedforward loop [12]. It would be 
important to characterize the expression of differentiation markers to better assess the 
ability of Vgll4 to delay differentiation and the ability of Nanog to inhibit it. 
Nanog overexpression was not sufficient to overcome treatment with endoderm 
or cardiac mesoderm-induction protocols. This would suggest that the use of direct 
inducers of differentiation is sufficient to destabilize the pluripotency transcriptional 
network despite overexpression of one of its components. This experiment also allows 
us to conclude that Vgll4 overexpression does not interfere with directed 
differentiation into these lineages. It would be interesting, however to more carefully 
study the timepoints at which these markers arise to determine if Vgll4 is delaying 
differentiation in this context. 
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Formation of teratomas with derivatives from the three germ layers were 
obtained for hES cells overexpressing, Nanog, GFP, or Vgll4. Interestingly, Vgll4 
teratomas were approximately 2-3 times the size of Nanog and GFP teratomas (data not 
shown). Since we were unable to assess continued lentiviral expression, we cannot 
make conclusions about the effect of these genes on the differentiation into certain 
lineages, but we can conclude that overexpression of these genes does not irreversibly 
affect the pluripotency of hES cells. This point would have to be examined more closely 
by directly comparing the efficiency of differentiation into specific cell types, for 
example by directed differentiation. Nevertheless, this point is important if, for 
instance, Vgll4 were to be used as a method to expand the numbers of pluripotent stem 
cells by increasing survival.  
Interestingly, downregulation of Vgll4 seems to have an effect on the expression 
levels of Nanog, and perhaps Oct4. The biological relevance of these changes remains to 
be characterized but it is suggestive of a role for Vgll4 in the stabilizing the pluripotent 
transcriptional network. Conversely, we detected increased levels of Vgll4 mRNA upon 
downregulating Nanog. One possible interpretation of this result is that Nanog and 
Vgll4 could regulate each other as part of a negative feedback loop. An alternative 
interpretation is that since Vgll4 increases upon differentiation, this represents an 
increase in a differentiated population. Also, the fact that N55 hairpins did not increase 
levels of Vgll4 despite considerable downregulation of Nanog presents a need for 
further investigation. 
The fact that Vgll4 did not positively affect the efficiency of reprogramming was 
surprising given the roles we have uncovered for this gene in hES cells, including 
 123 
 
survival, delay of differentiation and possible regulation of pluripotency genes. 
However, given the role of Vgll4 as a co-transcriptional regulator, and the widespread 
expression of TEAD factors, adding Vgll4 could be helping to stabilize the differentiated 
state. To further address this question, it would be interesting to test the response to 
addition of Vgll4 at different timepoints in the reprogramming process, especially later 
on. In addition, optimization of our reprogramming conditions, as explained above, 
should be helpful to draw a more definitive conclusion. It is interesting to point out that 
results from a recent study indicated that the TAZ co-transcriptional regulator is 
necessary for successful reprogramming [13]. As explained in Section 4 of this Chapter, 
if Vgll4 is acting as a negative regulator of the YAP and TAZ co-transcriptional 
regulators, the decrease in reprogramming efficiency that we observed would be 




4.3 A role for Vgll4 in the regulation of proliferation 
4.3.1. Rationale 
Overexpression of Vgll4 increased the rate of population doubling in a variety of 
pluripotent lines (please refer to Chapter 3, Section 3). This result could be explained by 
an increased rate of replication, a decrease in the rate of cell death, or a combination of 
these two mechanisms. For this purpose, we tested whether Vgll4 was affecting cell 
cycle dynamics in hES cells. 
4.3.2. Results 
To assess whether Vgll4 was affecting cell cycle dynamics in hES cells, we began by 
looking at the distribution of cells in different phases of the cell cycle. An assessment of 
cell cycle distribution in different transduced lines was achieved by measuring DNA 
content by propidium iodide (PI) staining and flow cytometry. In most cases tested 
using different pluripotent lines, Vgll4 did not seem to affect the distribution of cells in 
the cell cycle. However, we found it technically challenging to replicate this assay 
consistently in order to build strong statistics supporting our conclusion (Figure 4-9). 
To further explore whether Vgll4 was affecting cell cycle dynamics, we have begun 
to use markers for different phases of the cell cycle as a complementary way to get an 
accurate representation of cell cycle distribution. We used phospho-histone H3 (pH3) 
to detect the proportion of mitotic cells under self-renewing conditions 5-6 days after 
plating. We found a similar proportion of mitotic cells in our different cell lines (Figure 
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Figure 4-9. Distribution of cell populations in the cell cycle. Two representative 
experiments (a and b) are shown. Distribution of cells in the cell cycle was assessed by DNA 
quantification using PI staining. The Dean-Jett-Fox model was used for calculating the area under the 
curve. The reason behind G1, S, G2 percentages adding up to more than 100% is that the modeling 
algorithms contain some approximations and are rounded numbers.  
 
Figure 4-10. Proportion of mitotic cells in self-renewing hES cell lines. Human ES cell lines 
were fixed 5-6 days after plating and stained with Oct4, Human Nuclear Antigen (HuNu), phospho-
histone H3 (pH3) and DAPI. Panels to the left show representative images of mitotic cells and 
quantification is provided to the right. Significance was calculated using an unpaired Student’s T-test. 




We began to explore whether Vgll4 has a role in regulating cell cycle dynamics of 
hES cells that could contribute to the 2-3 fold higher population doubling rate observed 
in multiple cell lines. Even though our results from examining the distribution of cells in 
different phases of the cell cycle by assessing DNA content did not indicate a substantial 
difference, our approach was technically challenging to reproduce consistently and 
many experiments could not be analyzed because of too much noise in the sample. We 
think that these problems could be due to cell loss during sample preparation, cell 
aggregation during analysis, and inherent noise in PI labeling. Additionally, variations in 
the distribution of cells between experiments provide a challenge for statistical 
analysis. We were careful to use cells prepared exactly under the same conditions. 
Therefore, we think that these variations are not biologically significant and likely have 
to do with variables such as small differences in the density of cell culture upon 
harvesting. Finally, the Dean-Jett-Fox model for calculating the area under the curve 
gives a more accurate estimation of cell cycle distribution compared to regular gating. 
Nevertheless, the model requires a near perfect cell cycle outline to fit clearly, and if this 
is not the case, it rejects the data. An alternative is to do some manual adjustments of 
the model, but this does not get rid of the problem of noise in the samples.  
To overcome these challenges, we have begun to assess specific markers for cell 
cycle phases by flow cytometry and immunocytochemistry. This approach has a better 
signal-to-noise ratio than PI labeling and can provide us with more accurate 
information than the curve-fit algorithm. A caveat of our approaches so far, however, is 
that it they are only providing us a snapshot of the cell cycle distribution at a particular 
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timepoint. It is possible that the changes will be more noticeable at early timepoints 
after plating. Therefore, we are currently continuing to assess differences in markers of 
all phases of the cell cycle and exploring early and late timepoints after plating to detect 
any differences in the cell cycle distribution of our cell populations. Understanding 
whether Vgll4 alters cell cycle dynamics is instrumental to devise approaches to use 




4.4 A role for Vgll4 in the Hippo pathway 
4.4.1. Rationale 
 The Hippo pathway regulates, proliferation, apoptosis, differentiation, and organ 
size in flies and mammals. Components of this pathway in mammals are closely 
conserved to their counterparts in Drosophila [14]. Briefly, Mst1/2 kinase lies at the 
core of the pathway. Mechanisms for its activation are still being uncovered, but 
activated Mst1/2 phosphorylates and activates Lats1/2. Lats1/2, in turn 
phosphorylates and inhibits the co-transcriptional regulators Yap and Taz. Thus, when 
the Hippo pathway is inactive, Yap and Taz can translocate into the nucleus and interact 
with TEAD to promote gene expression [14-16]. Upstream activators of the pathway are 
still being discovered, but there is increasing evidence of a relation to cell polarity and 
adhesion [17, 18]. 
Besides its roles in tissue homeostasis, the Hippo pathway has been shown to play 
an important role in the initial cell fate decisions in the mouse embryo. Differential 
localization of Yap to the outside cells of the early embryo promotes activation of 
trophectoderm versus inner cell mass genes [18]. Interestingly, the Hippo pathway has 
also been shown to have a role in pluripotency. Yap has been shown to be important for 
mES cell self-renewal [19] and TAZ was shown to be necessary for iPS reprogramming 
[13]. Given its interactions with TEADs [20], we wondered if Vgll4 could be acting as a 
regulator of the Hippo pathway in hES cells. 
A previous study by Chen et al., identified Vgll4 as a negative regulator of TEAD-
mediated expression in murine cardiomyocytes [20]. Therefore, we were interested in 
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testing whether Vgll4 would be a negative regulator for TEAD-mediated activity. Our 
approach to this question was two-fold: First, we looked for downregulated TEAD 
target genes in our microarray data of WT hES cells versus hES cells overexpressing 
Vgll4. Second, we used a reporter cell line for TEAD activity to assess whether TEAD-





To test whether Vgll4 was a novel regulator of the Hippo pathway, we began by 
searching for evidence of downregulation of TEAD target genes in our microarray data 
from WT and Vgll4-overexpressing hES cells. CTGF (connective tissue growth factor) 
and CYR61 (cysteine-rich, angiogenic inducer, 61) have been shown to be direct target 
genes of the Hippo pathway in mammalian cells [14, 21, 22]. Both of these genes were 
significantly downregulated in hES cells in response to Vgll4 overexpression. 
Next, in collaboration with Fernando Camargo (Harvard University), we assessed 
the impact of Vgll4 overexpression on the activation of TEAD-mediated transcription by 
using a reporter plasmid for TEAD activity. This reporter, generated in the Camargo 
Lab, contains TEAD-binding sequences upstream of a luciferase gene. Cell were 
transfected with the reporter plasmid in addition to Vgll4, GFP (negative control) or 
Yap S127A (a constitutively active version of Yap, positive control). From this 
experiment, Vgll4 seems to have an inhibitory role in TEAD-mediated transcription 
(Figure 4-11). This agrees a previous report in the literature that suggests that Vgll4 
inhibits transcription activation in cardiomyocytes [20]. To our surprise, Vgll4 was even 
able to decrease the activation caused by constitutively active Yap. To ensure that this 
was not an artifact caused by halving the effective concentration of Yap S127A, we 
added a control where Yap S127A and GFP were co-transfected. This co-transfection 
did not alter the signal compared to S127A alone, indicating an effect for Vgll4 in 
decreasing TEAD-mediated transcription.  
To test the relevance of this result, we would ideally test it in hES cells to ensure 
the absence of cell-context specificity effects. Since decided to focus our efforts to 
 132 
 





















Figure 4-11. Vgll4 inhibits TEAD-mediated transcription in a reporter assay. 293T cells 
carried the reporter plasmid outlined in a). This reporter contains TEAD binding sequences in front 
of a luciferase gene. b) Cells were transfected the reporter plasmid and Renilla as a transfection 
control in addition to the indicated genes. Activation of the reporter was assessed as a function of 
luciferase/Renilla luminescence. Mock = treated only with transfection reagents, luc/R = transfected 
only with reporter plasmid and Renilla control, S127A = constitutively active Yap. Results represent 











Figure 4-12. Vgll4 downregulates Hippo pathway target genes in hES cells. Relative 
expression changes for pro-apoptotic genes in Vgll4 relative to WT hES cells were obtained by 
microarray analysis. The q-values for these changes in expression are: CTGF q = 0%; CYR61 q = 0%. 




The importance of the Hippo pathway for many cellular decisions is quickly 
becoming clear. We became interested in exploring a role for Vgll4 in this pathway 
because of its homology to members of the Drosophila signaling pathway, as well as its 
interaction with known effectors downstream of the Hippo pathway in mammalian 
cells. Our results suggest that Vgll4 may act as an inhibitor of transcriptional targets of 
TEAD transcription factors, consistent with a previous report. However, more work is 
necessary to fully understand and characterize a possible role for Vgll4 in this pathway.  
Nevertheless, the prospect of a novel inhibitor of the pathway is promising. Vgll4 
has been reported to be a negative regulator of TEAD-dependent gene expression in 
cardiomyocytes [20]. Given the roles reported for the Hippo pathway in mediating early 
cell fate decisions, self-renewal, and reprogramming, a negative regulator for this 
pathway would be interesting and important. TEAD target genes were downregulated 
upon Vgll4 overexpression in hES cells, suggesting that our observation in reporter cells 
might be relevant in the hES cell context. It is of note that this downregulation 
happened within the highest confidence interval and significance according to analysis 
with SAM. 
There is, nevertheless, an alternative explanation to these observations. It is 
possible that Vgll4 is altering the DNA-binding selectivity of TEAD, in a way competing 
it away from its known YAP-mediated targets. In Drosophila, Vg has been reported to 
change the DNA specificity of Scalloped (Sd), the TEAD homolog [23] through a 
mechanism that is not understood. In flies, this target selectivity allows the activation of 
a different set of genes by Sd depending on whether it is bound by Yorkie (Yki, the 
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Yap/Taz homolog) or by Vg. More work is necessary to determine whether our 
observed decrease in TEAD-mediated activity is caused by an inhibition of Yap-TEAD 
complexes by Vgll4 or by switching the target selectivity of TEAD when bound to Vgll4. 
The Hippo pathway was recently shown to have an important role in mediating 
one of the first cell fate decisions in the development of the mouse embryo: the 
trophectoderm versus inner cell mass specification. In this study, the authors find Yap 
localized to the nucleus of cells on the outside of the embryo that then go on to become 
trophectoderm. The authors propose that there might be a factor that interacts with 
TEAD and antagonizes Yap in inside cells to set up an inner cell mass program [18]. 
Additionally, there is increasing evidence for a role of the cytoskeleton and 
extracellular matrix cues as regulators of Hippo pathway signaling. A recent study 
suggests that Yap and Taz respond to ECM cues. In this context, Yap and Taz activity 
was dependent on Rho signaling [24], which has also been shown to promote the 
myosin hyperactivation leading to apoptosis in hES cells [25-27]. Of course, these 
studies were done with mammary epithelial cell lines and the relevance of these 
findings would have to be confirmed in hES cells, but it could suggest another 
interesting link with our findings from Chapter 3 and the possibility that Vgll4 and Rock 




4.5 A role for Vgll4 in the regulation of TGFβ signaling  
4.5.1. Rationale 
Vgll4 was originally identified in our screen as a gene whose expression allowed 
hES cells to maintain their pluripotent state in the presence of TGFβ inhibiton. One 
obvious explanation for this phenotype would be that Vgll4 was acting downstream in 
this pathway to counteract the inhibition of signaling. For this reason, we investigated 
whether the overexpressed Vgll4 could be acting downstream of the TGFβ receptor to 
restore activity of this signaling pathway, in the contest of receptor inhibition by SB-
431542. 
4.5.2. Results 
To detect TGFβ signaling activity, we used a mink lung epithelial reporter cell line. 
This cell line, known as TMLC, stably contains a portion of the plasminogen activator 
inhibitor 1 (PAI-1) promoter fused to a luciferase reporter gene [28] and has been 
widely used in the TGFβ-signaling field [29, 30]. We transduced these cells with GFP or 
Vgll4 and selected for successfully transduced cells with puromycin. These cells were 
then treated for 12 hours with the following treatments: vehicle control, TGFβ (50 
ng/ml), SB-431542 at 10 μM, and TGFβ+SB-431542. Following treatment, luciferase 
activity was measured (Figure 4-13). 
Unexpectedly, Vgll4 appeared to inhibit activation of the PAI-1 promoter. This 
result was surprising since we expected Vgll4 to counteract the effect of TGFβ inhibition 
in hES cells. Even though this experiment is informative, there are several caveats to the 
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interpretation of these results. First, it is necessary to rule out species- and cell-context 
specific effects. Especially given that Vgll4 is a co-transcriptional regulator, its effects 
could be context-dependent. Second, this assay is based on a single promoter. To better 
assess whether this is a global effect on TGFβ signaling, looking at a wider range of 
genes is necessary. This second point is especially important given that the molecules 
thought to be more important in hES cell pluripotency are Activin and Nodal [31-34]. 
Even though TGFβ signaling uses many of the same signal transducers, the effect on 









Figure 4-13. Vgll4 inhibits the activation of a gene target of TGFβ signaling. a) TMLC 
reporter cells carry a portion of the plasminogen activator inhibitor 1 (PAI-1) driving expression of a 
luciferase gene. b) TMLC lines overexpressing GFP or Vgll4 were treated with the indicated 






This result is puzzling given that Vgll4 was found as a gene that could overcome 
TGFβ inhibition as a means of inducing differentiation in hES cells. Unless Vgll4 
stabilizes other nodes of the pluripotency network despite the inhibition of this 
pathway, it would be difficult to reconcile this result in the context of hES cell 
maintenance. Additionally, hES cells transduced with Vgll4 can be maintained and 
passaged for over 30 passages without loss of pluripotency markers. An alternative 
explanation is that Vgll4 acts as a transcriptional repressor and that when expressed at 
higher levels it quenches regulators needed to activate TGFβ signaling. 
An alternative, and perhaps simpler, explanation is that PAI-1 (also known as 
SERPINE1) has been reported to be a target for Yap/TEAD [36]. Interestingly, several 
studies have shown an interaction between Yap and Taz and SMAD shuttling and 
signaling [37, 38]. The specific nature and domains of interaction between Yap, Taz, and 
Smads are unknown. However, if the interaction occurs through a domain shared 
between Yap, Taz, and Vgll4, then the overexpression of Vgll4 could sequester Smad. 
There is currently no evidence to support a direct interaction between Vgll4 and Yap or 
Taz, although that could be an alternative explanation. Nevertheless, it is still difficult to 
reconcile this result with the observed phenotype of hES cell maintenance. 
4.6 Concluding remarks 
Overall, the activity of Vgll4 seems to be complex and to span more than one mode 
of action. In this chapter we explored four possible mechanisms for Vgll4 activity and 
found evidence to support a role in most of them. We are aware that these results need 
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to be extensively verified but we hope that they would serve as a foundation for further 




4.7 Methods used in this chapter 
4.7.1. hES cell culture 
HUES6 were plated on irradiated murine embryonic fibroblasts (MEFs) and grown 
in media containing KO-DMEM (Invitrogen), 10% Knockout Serum Replacement (KOSR, 
GIBCO), 10% human plasma fraction (Talecris), 2 mM L-glutamine (Invitrogen), 0.1 mM 
non-essential amino acids (GIBCO), .055 mM β-Mercaptoethanol (GIBCO), and 10 ng/ml 
bFGF (Invitrogen). Cultures were passaged using 0.05% Trypsin-EDTA (GIBCO) at a 
ratio of 1:6-1:10 every 5-7 days. 
Where indicated, SB-431542 was used at a concentration of 10 μM, SU-5402 at 20 
μM. Both of these were resuspended in DMSO. DMSO vehicle controls were made with 
the equivalent volume of DMSO of the two chemicals combined. Retinoic Acid was used 
at a final concentration of 10 μM. 
MEFs were plated on plates coated with 0.1% gelatin. MEF media contained 1X 
DMEM (Mediatech), 10% FBS, 2mM L-glutamine (Invitrogen), and 0.1mM non-essential 
amino acids (GIBCO). 
4.7.2. Assessment of pluripotency markers by flow cytometry 
Cells transduced with Nanog, GFP, or untransduced (WT) were cultured in the 
presence of 10 μM SB431542 (TGFbi) or with vehicle control (the equivalent amount of 
DMSO). Cells were passaged every 5-7 days. A fraction of cells was re-plated and the 
rest was used to analyze the level of pluripotency markers by FACS analysis. After 
washing the pellet with PBS, the cells were resuspended in a 1:100 dilution of Tra1-60 
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antibody (Millipore) and incubated on ice for 40 minutes. Cells were then washed and 
resuspended in a secondary antibody solution of APC-conjugated donkey anti-mouse 
IgM (Jackson Immunoresearch) at a concentration of 1:300. Cells were incubated for 20 
minutes on ice. Following this incubation, cells were washed and resuspended in FACS 
buffer (PBS containing 5% Hyclone serum). APC-positive cells were quantified using a 
BD LSR II and FACSDiva. 
4.7.3. Real-time PCR throughout EB differentiation 
hESCs transduced with the indicated genes were gently trypsinized and placed in a 
low-attachment 6-well dish at a concentration of 1x106 cells/well in hES cell medium 
without bFGF. Cells were left undisturbed for the first 96 hours to allow for formation of 
individual EBs and media was changed every 48 hours thereafter. A fraction of EBs 
were collected at the indicated times and used as a source of RNA. 
RNA was harvested using a Qiagen RNeasy kit. DNAse I treatment was used as 
indicated by the manufacturer to eliminate genomic DNA. Purified RNA was used as 
input for the reverse transcription reaction using the Superscript III First Strand kit 
(Invitrogen). TaqMan assays (Applied Biosystems) were used for the following human 
genes and samples were prepared following manufacturer instructions: POU5F1, 
NANOG, VGLL4. GAPDH was used as a control. All samples were analyzed using an 
HT7900 machine (Applied Biosystems) using the Fast protocol. Resulting Ct values 




4.7.4. Endoderm and cardiac mesoderm differentiation 
For directed differentiation into endoderm progenitors, HUES6 hES cells were 
treated with RPMI, 0% FBS, PenStrep, Glutamax, Activin A (100 ng/ml), and Wnt3a (20 
ng/ml) for 24 hours. Cells were then switched to RPMI, 0.2% FBS, PenStrep, Glutamax, 
and Activin A (100 ng/ml) for 48 hours. Sox17 was stained using goat anti-Sox17 
(1:500, R&D Technologies) and FoxA2 was stained using rabbit anti-FoxA2 (1:500, 
Upstate). 
For directed differentiation into cardiac progenitors, HUES6 hES cells were treated 
with RPMI, 0.2% FBS, PenStrep, Glutamax and Activin A (50 ng/ml) for 48 hours. Cells 
were then switched to RPMI, 2% FBS, PenStrep, Glutamax, Bmp4 (20 ng/ml) and Wnt3a 
(20 ng/ml) for 5 days with a media change on the third day. Nkx2.5 was stained using 
rabbit anti-Nkx2.5 (1:100, Santa Cruz Biotechnology) and Isl1 using mAb anti-Isl1 
(1:100, Developmental Studies Hybridoma Bank clone 39.3F7). 
4.7.5. Teratoma formation 
3 x 106 to 1 x 107 hES cells overexpressing Nanog, GFP, or Vgll4 were resuspended 
in hES-grade Matrigel (BD) and injected under the kidney capsule of SCID-Beige mice. 
30-45 days later, mice were sacrificed and the teratoma was isolated. Tissues were 




4.7.6. shRNA knockdown 
ssDNA oligos were obtained from Invitrogen for Vgll4 (V76: Hmi423276; V77: 
Hmi423277; V78: Hmi423278) and Nanog (N52: Hmi475552; N53: Hmi475553; N55: 
Hmi475555) and processed using the instructions for the BLOCK-iT Pol II miR RNAi 
Expression Vector Kits. shRNAs were cloned into the EF1α-pDEST using Gateway 
cloning to use the same vector used in our screening strategy. Sequences were verified 
using Geneious. Lentiviral particles were made as outlined in Chapter 2. Cells were 
transduced with the lentiviral shRNA constructs as indicated in the transduction section 
in previous chapters and selected with puromycin. Cells were maintained in hESC 
medium for 7 days after selection. After this timepoint cells were collected for RNA 
analysis or maintained as described above for subsequent analyses.  
4.7.7. Reprogramming into iPS cells 
Protocol adapted from Kit Rodolfa (Eggan Lab, Harvard University).  
Human fibroblasts were seeded at 30,000 cells per well in a gelatinized 6-well dish 
and grown overnight in MEF medium. Cells were transduced using an MOI of 10-15 
each of KLF4, SOX2, and OCT4. Retroviruses (obtained from the Harvard Gene Therapy 
Initiative) were generated by tripartite transfection in 293T cells and concentrated by 
ultracentrifuge to ~109 viral particles/ml. Additionally, EF1α-pHAGE lentivirus for GFP 
or Vgll4 was added at an MOI of 10. An additional control with no lentivirus was also 
included. Cells were incubated in hES cell medium containing 8 μg/ml polybrene (Sigma 
Aldrich). Cells were incubated with virus for 6-12 hours and supplemented (without 
removing virus-containing medium) with 1 ml of MEF medium containing 8 μg/ml 
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polybrene. Cells were left in this medium for a further 48 hours and then the medium 
was removed carefully and replaced with hES cell medium for the duration of the 
experiment. Subsequently, medium was replaced daily.  
4.7.8. Cell cycle dynamics by flow cytometry 
hES cells were trypsinized and MEF-depleted by plating on gelatin-coated plates 
for 45 minutes. 1 - 4 x 106 cells were resuspended in 0.5 ml PBS followed by the 
addition of 0.5 ml of 100% ice-cold ethanol to the cells in a drop-wise manner while 
vortexing. After incubation for a minimum of 20 minutes on ice, cells were harvested by 
centrifugation (1000 rpm for 5-7 minutes) and the ethanol was decanted. Finally, 1 ml 
of Propidium Iodide-RNAse solution [(final concentrations 100 μg/ml PI (Molecular 
Probes) + 10 μg/ml RNAse Type I-A (CONCERT, Invitrogen) in PBS)] was added to the 
cells. After 30 minutes of incubation, the samples were analyzed by flow-cytometry by 
using BD-LSRII and FACSDiva. FlowJo analysis was used to determine the relative 
percentage of cells in different stages of the cell cycle using the Dean-Jett-Fox model. 
4.7.9. Mitotic cell assessment by immunofluorescence 
Cells were washed with PBS and fixed for 30 min with a 4% paraformaldehyde 
solution. Cells were then blocked using 5% donkey serum and stained with the 
following antibodies: anti-Oct-4 (1:200, Santa Cruz Biotechnology), anti-Human Nuclear 
Antigen (1:100, Millipore), anti-Phospho-histone H3 (1:100, Millipore). Appropriate 
secondary antibodies produced in donkey and fluorescently conjugated were acquired 
from Molecular Probes and used at a 1:300 dilution. Incubations with primary 
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antibodies were done overnight at 4°C. Secondary antibodies were incubated for 1 hr at 
room temperature or overnight at 4°C. Cell nuclei were stained with DAPI for 20 
minutes at room temperature. Image-based quantification was done using a Cellomics 
system. 
4.7.10. Hippo pathway activation 
293T cells were transfected with the TEAD reporter plasmid (obtained from the 
Camargo lab, Harvard University). A day before transfection, ~1x106 were plated per 
well of a 24-well plate. The next day as per manufacturer’s instructions, 1.5 μl of 
TRANS-IT 293 (MirusBio) and 50 μl Optimem (GIBCO) were mixed thoroughly and 
incubated at room temperature for 5-10 minutes. Following this incubation, 51.5 μl of 
Mirus/Optimem mix was added to 0.44 μg of DNA with very gentle mixing and 
incubated for 20 minutes at room temperature. After this incubation, the mix was 
added dropwise onto the cells and mixed gently by moving the plate back and forth. For 
each reaction, 0.2 μg of TEAD reporter plasmid and 0.04 μg of Renilla control were 
mixed with 0.2 μg of the indicated DNA. In the case of co-transfections, 0.1 μg of each 
gene was used. Cells were lysed 24 hours post-transfection and analyzed with Renilla 
Luciferase lysis buffer (Promega). 2 μl of lysates was then aliquoted into a 96-well. 
Luminometer dispensed 50 μl of assay buffer per well and integrated luminescence 




4.7.11. Microarray analysis 
RNA was purified from samples in quadruplicates using a Qiagen RNeasy kit and 
200 ng of starting material were used as input for the Illumina TotalPrep Amplification 
Kit. Samples were then hybridized to an Illumina microarray. A selection of significantly 
different genes was analyzed using SAM. Network and gene ontology analyses were 
performed using GeneGO. 
4.7.12. Assessment of TGFβ signaling 
TMLC cells were maintained in MEF media (described in hES culture section 
above). Cells were incubated with lentiviruses for GFP or Vgll4 at an MOI of 1-2 
overnight. Cells were allowed to recover for 48 hours and then selected with 2 μg/ml of 
puromycin for 48 hours. 
Cells were then trypsinized using 0.25% Trypsin/EDTA (Gibco) and 1x105 of cells 
were plated per well of a 96-well plate in the presence of DMSO, rhTGFβ-1 at 50 ng/ml 
(R&D Systems), 10 μM SB-431542 (Sigma Aldrich), or a combination of 50 ng/ml TGFβ-
1 and 10 μM SB-431542. Cells were incubated in treatment conditions for 24 hours and 
subsequently lysed using a Luciferase Assay Kit (Promega). Luminescence was 
measured using a luminometer.  
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4.8 Note regarding author contributions 
Dr. Justin Annes helped with the quantification of pH3 staining and with the design 
of the experiment to explore a role for Vgll4 in TGFβ signaling.  
Experiments to determine a role for Vgll4 in the Hippo pathway were designed, 
performed, and analyzed in collaboration with Dr. Morvarid Mohseni (Camargo Lab, 
Harvard University). 
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Chapter 5  
Concluding Discussion and Future Directions 
Embryonic stem cells represent an opportunity to realize the goals of regenerative 
medicine. Despite great progress in the field, the medical potential of hES cells is 
hindered by their propensity for spontaneous differentiation, poor survival of low-
density cultures, and difficulty recovering cells after freezing. In this dissertation, we 
devised a genetic approach to uncover genes participating in maintaining the self-
renewal of hES cells. From our screening and verification efforts, we identified Vgll4, a 
co-transcriptional regulator with no previously described role in ES cells. We found that 
Vgll4 can improve hES cell survival after dissociation, a finding with potential 
implications for improving the efficiency of hES cultures, especially at lower densities. 
We also explored other possible mechanisms for Vgll4 activity and found that it could 
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be participating in a variety of processes that ultimately contribute to the maintenance 
of the embryonic stem cell state in hES cells. 
Our genetic gain-of-function screen was based on the rationale that inhibition of 
TGFβ would allow us to find genes whose overexpression could rescue inhibition of this 
pathway to maintain self-renewal. Nanog was identified using a similar approach in 
mES cells, where cells deficient for the LIF receptor were screened for genes that could 
still maintain the cells in feeder-free conditions and in the absence of LIF [1]. 
Intriguingly, many of the genes that were hits in this screen seemed to be involved in a 
response to stress and modulation of cell death, indicating that these conditions were 
also allowing us to discover genes involved in hES cell survival. This could be due to a 
universal stress-response for ES cells in the presence of differentiation conditions. The 
latter possibility is strengthened by the observation of a large increase in cell death 
upon differentiation induction, as observed routinely in our laboratory. This 
observation also supports our view that mechanisms maintaining pluripotency, 
inhibiting differentiation, and promoting survival and proliferation must be closely 
intertwined in hES cells. 
Vgll4 was independently identified as a hit several times in our screen, an event 
with very low probability. In addition, it consistently was able to maintain hES cell 
colony morphology and pluripotency marker expression after five days of treatment 
with inhibitors for both TGFβ/Activin/Nodal and FGF signaling, suggesting a potent 
ability to promote pluripotency and survival. Vgll4 is a co-transcriptional regulator, 
which could mean a more direct role in mediating cellular decisions. However, the 
function of Vgll4 in hES cells represented a completely open book; in mammals, Vgll4 
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had only been described to have a role in heart development in the mouse. In addition 
to that study, data from the homologous gene in Drosophila, Vg, suggested multiple 
avenues for a role for Vgll4. In Drosophila, Vg is necessary for wing development and for 
the proliferation of precursor cells of the wing imaginal disc [2, 3]. Studies in Drosophila 
link Vg to survival and proliferation. For instance, in the absence of Vg, cells in the 
presumptive region of the larval imaginal discs undergo extensive cell death, resulting 
in complete absence of the wing in adults [4]. Vg interacts with Scalloped (Sd), the 
Drosophila homolog of TEAD. Together, Vg and Sd regulate the expression of multiple 
genes affecting cell proliferation and differentiation of the wing [5]. Together, these 
studies point to a possible role for Vg mammalian orthologs in the survival, 
proliferation, and differentiation of multipotent cell populations.  
A striking and consistent observation was an increase in the population-doubling 
rate of cells overexpressing Vgll4. We reasoned that this observation could result from 
increased cell proliferation, a decrease in cell death, or both. We began by exploring a 
role in promoting survival, as cell death in response to dissociation is a unique problem 
to hES cells with important implications for harnessing the therapeutic potential of 
these cells [7]. Vgll4 promoted survival of hES cells in self-renewal conditions as well as 
hES cells where E-cadherin junctions were compromised. E-cadherin junctions have 
been reported to control upstream signaling leading to cell death through the Rho/Rock 
pathway in response to dissociation in hES cells [7-9]. Our data indicates that Vgll4 is 
able to promote survival of hES cells by decreasing caspase activation. It would be 
fascinating to understand how Vgll4 is exerting this effect and whether it is through a 
direct or indirect interaction with caspases, members of the Rho/Rock pathway or 
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other components of the apoptosis cascade. Additionally, global transcriptional analysis 
shows that many apoptosis and cytoskeleton genes are downregulated in the presence 
of Vgll4 overexpression. Many members of the apoptosis pathway are regulated post-
translationally, but it is also possible that overall protein levels are lower in Vgll4 cells, 
leading to a weaker activation of the cell death response. Alternatively, Vgll4 could be 
regulating a cytoskeleton response to promote cell survival. One possibility is that Vgll4 
could prevent the myosin hyperactivation that leads to cell death or that by regulating 
cytoskeleton genes cell-to-cell junctions are more resistant to disruption. We observed 
that levels of activated caspases are higher than baseline when Vgll4 is downregulated 
by shRNA. This result suggests that Vgll4 is necessary for regulating caspase activation 
in response to dissociation. However, further decreasing the levels of Vgll4 with more 
effective shRNAs, TALEN nucleases [10], zinc-finger nucleases [11], or traditional 
knockouts would allow us to explore this phenotype further and more conclusively. 
Additionally, this would allow us to test for an effect in the population rate –whether it 
is lower in the absence of Vgll4– implying an important role in the population 
maintenance of hES cells. 
Another question stemming from the observation that Vgll4 contributes to a 
higher population-doubling rate is whether Vgll4 is contributing to an increase in cell 
cycle or altering the dynamics of cell cycle. Our initial observations have not detected a 
difference in terms of population distribution across the cell cycle or number of mitotic 
cells in cells overexpressing Vgll4. However, we believe more that more thorough 
analysis is needed to make a definitive conclusion. To this end, we will examine specific 
markers for different phases of the cell cycle at early and late timepoints after plating, 
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with the rationale that the effect of Vgll4 might be easier to detect when the population 
is just starting to expand after passaging.  
The effect of Vgll4 in affecting cytoskeleton gene expression encourages us to 
explore whether Vgll4 is contributing to the cell-dissociation response through the 
Rho/Rock pathway. It would be interesting to understand if and how Vgll4 interacts in 
this pathway and if it could be exploited as a way of improving cell survival further from 
the levels achieved with Rock inhibitor Y-27632 [12]. Importantly, Vgll4 has a 
significant effect in increasing the colony formation efficiency from single cells. Some of 
the major roadblocks in hES cell biology currently lie in the lack of genetic tools similar 
to those available for mouse. Generating reporter cell lines would allow the 
optimization of differentiation protocols by providing and efficient way of identifying 
cells of interest. Given the low efficiency of homologous recombination, the ability to 
generate reporter cell lines hinges on our ability to increase survival of hES cells from 
clonal densities.  
In this dissertation, we have concentrated on elucidating a role for Vgll4 in hES 
cells. However, it is possible that Vgll4 has other effects in different cell types, especially 
since it is expressed in a variety of adult tissues [13]. We began to explore a role for 
Vgll4 in the survival of normal human dermal fibroblasts and human vascular 
endothelial cells. The absence of an observed effect in our assays is likely due to the fact 
that these cells are not sensitive to dissociation. Therefore, in the context of hES cells 
and other specialized cell types, it would be interesting to explore whether Vgll4 is a 
universal regulator of survival that can protect cells from apoptosis in the presence of 
other death-induction mechanisms. For instance, insights into whether Vgll4 can 
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overcome overexpression of TNF receptor, Fas-ligand, or other apoptotic cues would be 
interesting and could have implications for other diseases and therapies in humans. 
As part of this dissertation, we explored several mechanisms of action for Vgll4 in 
hES cells. We found evidence that Vgll4 could be delaying the progression of 
differentiation at early stages as assessed by maintenance of colony morphology and 
pluripotency marker expression in the presence of differentiation cues. However, we 
found that this delay is temporary –cells ultimately differentiate despite Vgll4 
overexpression. Nevertheless, this observation together with a possible downregulation 
of some of these pluripotency markers upon Vgll4 knockdown could indicate a subtle 
but important role for Vgll4 in stabilizing the pluripotency network. We have begun 
exploring the gene targets for Vgll4 regulation by ChIP-Seq as well as protein-protein 
interactions by Mass Spectrometry in collaboration with Dr. Laurie Boyer (MIT). These 
results will shed more light into the mechanism of action of Vgll4 and other key 
regulators of its function. 
Based on evolutionarily conserved interactions of Vestigial-family genes with 
TEAD transcription factors, we decided to look at the recently described Hippo pathway 
as a possible mechanism for Vgll4 functions. Many reasons point to a possible role in 
this pathway: the conserved interaction with TEADs, the recent studies suggesting roles 
for TEADs and Hippo signaling in early embryonic development [14], stem cell self-
renewal and reprogramming [15, 16], and the connection between members of the 
Hippo pathway and cytoskeleton regulation [17]. Vgll4 has been described as a 
transcriptional repressor [13], and we find that it has a powerful effect in inhibiting 
TEAD-mediated transcription in a reporter cell line context. An immediate next step 
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would involve verifying a similar role in hES cells; our microarray data already shows 
significant downregulation of bona fide Hippo/TEAD gene targets. In addition, it would 
be interesting to test whether these genes are upregulated in response to Vgll4 
knockdown and whether reporter activity increases in response to Vgll4 
downregulation. Establishing a link to the Hippo pathway could establish Vgll4 as a 
novel regulator of the Hippo pathway and could have implications for the variety of 
regulatory functions that Hippo has been linked to including organ size regulation [18-
22], tissue homeostasis [23], and cancer [24]. 
In closing, this dissertation has explored genetic approaches to understanding 
molecular mechanisms involved in hES cell maintenance. We have identified Vgll4 as a 
novel regulator in hES cell survival. This finding represents an opportunity to improve 
cell survival for the application of hES cells in regenerative medicine. We also conclude 
that Vgll4 is a gene with a complex mode of action, and propose some of the pathways 
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